1
|
Takemoto T, Kiriyama I, Sugawara Y, Abe C, Teramoto N, Hashine K, Yoshida I, Asagi A. A case of EBV-associated adrenal leiomyoma. Radiol Case Rep 2024; 19:2224-2229. [PMID: 38523717 PMCID: PMC10959640 DOI: 10.1016/j.radcr.2024.02.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Revised: 02/13/2024] [Accepted: 02/14/2024] [Indexed: 03/26/2024] Open
Abstract
Adrenal leiomyomas are rare and often reported as Epstein-Barr virus (EBV)-associated smooth muscle tumor (SMT) in association with EBV infection in immunocompromised patients. We experienced a case of right adrenal leiomyoma that was incidentally found in a man in his 70s. Computed Tomography (CT) showed a well-circumscribed mass of 3.1 cm in diameter in the right adrenal gland, which increased to 4.9 cm in diameter over 1 year. Preoperative diagnosis was difficult due to the lack of specific imaging findings. He had a history of diffuse large B-cell lymphoma (DLBCL) 8 years ago, and EBV had been detected in his blood. EBV-encoded small RNA(EBER) in situ hybridization (EBER-ISH) of the right adrenal leiomyoma was positive, and the final diagnosis was EBV-associated leiomyoma.
Collapse
Affiliation(s)
- Takumasa Takemoto
- Department of Diagnostic Radiology, NHO Shikoku Cancer Center, Matsuyama, Japan
| | - Ikuko Kiriyama
- Department of Diagnostic Radiology, NHO Shikoku Cancer Center, Matsuyama, Japan
| | - Yoshifumi Sugawara
- Department of Diagnostic Radiology, NHO Shikoku Cancer Center, Matsuyama, Japan
| | - Chie Abe
- Department of Pathology, NHO Fukuokahigashi Medical Center, Koga, Japan
| | - Norihiro Teramoto
- Department of Pathology, NHO Shikoku Cancer Center, Matsuyama, Japan
| | | | - Isao Yoshida
- Department of Hematologic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan
| | - Akinori Asagi
- Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
2
|
Kawakami F, Yanai H, Teramoto N, Miyama Y, Yasuda M, Minamiguchi S, Iwamoto M, Kiyokawa T, Mikami Y. Concordance Between Biopsy and Resection Diagnoses of Uterine Cervical Adenocarcinoma According to the Updated World Health Organization 2020 Classification: A Multi-Institutional Study Elucidating Real-World Practice in Japan. Arch Pathol Lab Med 2024:498665. [PMID: 38282572 DOI: 10.5858/arpa.2023-0360-oa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2023] [Indexed: 01/30/2024]
Abstract
CONTEXT.— Endocervical adenocarcinoma is divided into human papillomavirus (HPV)-associated (HPVA) and HPV-independent (HPVI) in the 5h edition of the World Health Organization (WHO) tumor classification launched in 2020. However, the validity of the morphological criteria used for biopsy specimens in real-world practice remains undetermined. OBJECTIVE.— To validate the utility of the 5th edition of the WHO classification for biopsy samples, focusing on its diagnostic criteria with the aid of ancillary studies. DESIGN.— We retrieved 217 cases of endocervical adenocarcinoma from 6 institutions, in which glass slides of both biopsy and resection specimens were available for review. Concordance between the biopsy and resection specimen diagnoses was evaluated. For discordant diagnoses, an algorithmic approach with ancillary studies proposed by the international group was applied to confirm their utility to improve the accuracy of biopsy diagnosis. RESULTS.— The biopsy diagnosis matched the resection specimen diagnosis in 197 cases (concordance rate, 91%; κ = 0.75). The concordance rate was significantly higher for HPVA than HPVI (95% versus 81%, P = .001). There were no significant differences in the proportions of HPVA and HPVI or the accuracy of biopsy diagnosis between the participating institutions. All 19 discordant cases with unstained glass slides available were accurately recategorized as HPVA or HPVI using HPV in situ hybridization; p16 immunohistochemistry was positive in 3 of 9 cases of gastric-type HPVI that were negative by in situ hybridization. CONCLUSIONS.— The 5th edition of the WHO criteria for biopsy diagnosis of endocervical adenocarcinoma distinguishes HPVA from HPVI well when ancillary studies are adequately applied.
Collapse
Affiliation(s)
- Fumi Kawakami
- From the Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Kumamoto, Japan (Kawakami, Mikami)
| | - Hiroyuki Yanai
- Department of Pathology, Okayama University Hospital, Okayama, Okayama, Japan (Yanai)
| | - Norihiro Teramoto
- Department of Diagnostic Pathology, Shikoku Cancer Center, Matsuyama, Ehime, Japan (Teramoto)
| | - Yu Miyama
- Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan (Miyama, Yasuda)
| | - Masanori Yasuda
- Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan (Miyama, Yasuda)
| | - Sachiko Minamiguchi
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Kyoto, Japan (Minamiguchi)
| | - Masami Iwamoto
- Department of Pathology, Jikei University School of Medicine, Tokyo, Japan (Iwamoto, Kiyokawa)
| | - Takako Kiyokawa
- Department of Pathology, Jikei University School of Medicine, Tokyo, Japan (Iwamoto, Kiyokawa)
| | - Yoshiki Mikami
- From the Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Kumamoto, Japan (Kawakami, Mikami)
| |
Collapse
|
3
|
Hoshida Y, Tsujii A, Ohshima S, Saeki Y, Yagita M, Miyamura T, Katayama M, Kawasaki T, Hiramatsu Y, Oshima H, Murayama T, Higa S, Kuraoka K, Hirano F, Ichikawa K, Kurosawa M, Suzuki H, Chiba N, Sugiyama T, Minami Y, Niino H, Ihata A, Saito I, Mitsuo A, Maejima T, Kawashima A, Tsutani H, Takahi K, Kasai T, Shinno Y, Tachiyama Y, Teramoto N, Taguchi K, Naito S, Yoshizawa S, Ito M, Suenaga Y, Mori S, Nagakura S, Yoshikawa N, Nomoto M, Ueda A, Nagaoka S, Tsuura Y, Setoguchi K, Sugii S, Abe A, Sugaya T, Sugahara H, Fujita S, Kunugiza Y, Iizuka N, Yoshihara R, Yabe H, Fujisaki T, Morii E, Takeshita M, Sato M, Saito K, Matsui K, Tomita Y, Furukawa H, Tohma S. Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders. Arthritis Rheumatol 2024. [PMID: 38272827 DOI: 10.1002/art.42809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 01/06/2024] [Accepted: 01/22/2024] [Indexed: 01/27/2024]
Abstract
OBJECTIVE In this study, we examine how advancements in novel antirheumatic drugs affect the clinicopathologic features of lymphoproliferative disorder (LPD) in patients with rheumatoid arthritis (RA). METHODS In this multicenter study across 53 hospitals in Japan, we characterized patients with RA who developed LPDs and visited the hospitals between January 1999 and March 2021. The statistical tools used included Fisher's exact test, the Mann-Whitney U-test, the log-rank test, logistic regression analysis, and Cox proportional hazards models. RESULTS Overall, 752 patients with RA-associated LPD (RA-LPD) and 770 with sporadic LPD were included in the study. We observed significant differences in the clinicopathologic features between patients with RA-LPD and those with sporadic LPD. Histopathological analysis revealed a high frequency of LPD-associated immunosuppressive conditions. Furthermore, patients with RA-LPD were evaluated based on the antirheumatic drugs administered. The methotrexate (MTX) plus tacrolimus and MTX plus tumor necrosis factor inhibitor (TNFi) groups had different affected site frequencies and histologic subtypes than the MTX-only group. Moreover, MTX and TNFi may synergistically affect susceptibility to Epstein-Barr virus infection. In case of antirheumatic drugs administered after LPD onset, tocilizumab (TCZ)-only therapy was associated with lower frequency of regrowth after spontaneous regression than other regimens. CONCLUSION Antirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA-LPD, with patterns changing over time. Furthermore, TCZ-only regimens are recommended after LPD onset.
Collapse
Affiliation(s)
- Yoshihiko Hoshida
- National Health Organization (NHO) Osaka Minami Medical Center, Osaka, Japan
| | - Atsuko Tsujii
- National Health Organization (NHO) Osaka Minami Medical Center, Osaka, Japan
| | - Shiro Ohshima
- National Health Organization (NHO) Osaka Minami Medical Center, Osaka, Japan
| | - Yukihiko Saeki
- National Health Organization (NHO) Osaka Minami Medical Center, Osaka, Japan
| | - Masato Yagita
- Tazuke-Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan
| | | | | | | | | | | | | | | | - Kazuya Kuraoka
- NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan
| | | | | | | | | | | | | | - Yuko Minami
- NHO Ibarakihigashi National Hospital, Tokai, Japan
| | | | | | - Ikuo Saito
- NHO Sagamihara National Hospital, Sagamihara, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Keigo Setoguchi
- Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
| | - Shoji Sugii
- Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan
| | - Asami Abe
- Niigata Rheumatic Center, Shibata, Japan
| | | | | | | | - Yasuo Kunugiza
- Japan Community Health Care Organization Hoshigaoka Medical Center, Hirakata, Japan
| | | | | | | | | | | | | | - Masakazu Sato
- Kurashiki University of Science and the Arts, Kurashiki, Japan
| | - Kazuyoshi Saito
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | - Yasuhiko Tomita
- International University of Health and Welfare, Narita, Japan
| | | | | |
Collapse
|
4
|
Sugihara T, Teramoto N, Shigematsu H, Nakashima S, Ryuko T, Ueno T, Suehisa H, Abe C, Takahata H, Kato Y, Ninomiya T, Harada D, Kozuki T, Yamashita M. Benign Mesothelial Cells in transbronchial biopsy specimens: A potential diagnostic pitfall for lung cancer. Pathol Res Pract 2024; 253:154967. [PMID: 38064868 DOI: 10.1016/j.prp.2023.154967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/21/2023] [Accepted: 11/21/2023] [Indexed: 01/24/2024]
Abstract
Bronchoscopy is a common diagnostic procedure used to identify lung cancer. Specimens acquired through transbronchial biopsy are pivotal in the diagnosis and molecular characterization of this disease. The occurrence of benign mesothelial cells during a transbronchial biopsy (TBB) is relatively rare. Furthermore, these lesions can sometimes be erroneously identified as malignant, potentially resulting in unwarranted or inappropriate treatment for patients with and without lung cancer. In this retrospective analysis, we examined 619 TBB cases at our institute from 2019 to 2021. Benign mesothelial cells were identified via immunohistochemical studies in eight (1.3%) of 619 cases. These cells were classified into three patterns based on their cellular morphology: monolayer, lace, and cobblestone. Recognizing this phenomenon during the procedure is crucial to accurately distinguish benign mesothelial cells from their cancerous counterparts.
Collapse
Affiliation(s)
- Takahito Sugihara
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan.
| | - Norihiro Teramoto
- Department of Pathology, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Hisayuki Shigematsu
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Shohei Nakashima
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Tsuyoshi Ryuko
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Tsuyoshi Ueno
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Hiroshi Suehisa
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Chie Abe
- Department of Pathology, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Hiroyuki Takahata
- Department of Pathology, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Yuka Kato
- Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Takashi Ninomiya
- Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Daijiro Harada
- Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Toshiyuki Kozuki
- Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| | - Motohiro Yamashita
- Department of Thoracic Surgery, NHO Shikoku Cancer Center, 160 Kou, Minami Umemoto-machi, Matsuyama, Ehime 791-0280, Japan
| |
Collapse
|
5
|
Hibino Y, Okazawa-Sakai M, Yokoyama T, Fujimoto E, Okame S, Teramoto N, Takehara K. Abnormal Vaginal Cytology after Total Laparoscopic Hysterectomy in Patients with Cervical Intraepithelial Neoplasia. Acta Med Okayama 2023; 77:627-634. [PMID: 38145937 DOI: 10.18926/amo/66155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2023]
Abstract
To explore the incidence of abnormal vaginal cytology after total laparoscopic hysterectomy for the treatment of cervical intraepithelial neoplasia 3, we retrospectively analyzed the medical records of patients treated at NHO Shikoku Cancer Center (Japan) in 2014-2019. The cases of 99 patients who underwent a laparoscopic (n=36) or open (n=63) hysterectomy and postoperative follow-up were examined. Abnormal vaginal cytology was detected in 13.9% (5/36) of the laparoscopic-surgery (LS) group and 14.3% (9/63) of the open-surgery (OS) group. A vaginal biopsy was performed at the physicians' discretion; one LS patient and six OS patients were diagnosed with vaginal intraepithelial neoplasia. The cumulative incidence of abnormal vaginal cytology at 3 years post-hysterectomy was 21.4% (LS group) and 20.5% (OS group), a nonsignificant difference. A multivariate analysis showed that age > 50 years was the only independent risk factor for abnormal vaginal cytology among the covariates examined including age; body mass index; histories of vaginal delivery, abdominal surgery, and smoking; and surgical approach (hazard ratio 8.11; 95% confidence interval 1.73-37.98; p=0.01). These results suggest that the occurrence of abnormal vaginal cytology after a hysterectomy may not be influenced by the laparoscopic procedure but is associated with older age.
Collapse
Affiliation(s)
- Yumi Hibino
- Department of Gynecologic Oncology, NHO Shikoku Cancer Center
| | | | | | - Etsuko Fujimoto
- Department of Gynecologic Oncology, NHO Shikoku Cancer Center
| | - Shinichi Okame
- Department of Gynecologic Oncology, NHO Shikoku Cancer Center
| | | | | |
Collapse
|
6
|
Kawakami F, Yamaguchi K, Minamiguchi S, Sudo T, Hirose T, Teramoto N, Mikami Y. Endometrial gastric-type mucinous carcinoma: A clinicopathological study of an unfavorable histological type of endometrial carcinoma. Pathol Int 2023; 73:609-611. [PMID: 37671817 DOI: 10.1111/pin.13376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 08/18/2023] [Indexed: 09/07/2023]
Affiliation(s)
- Fumi Kawakami
- Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan
| | - Ken Yamaguchi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Tamotsu Sudo
- Section of Translational Research, Hyogo Cancer Center, Hyogo, Japan
| | - Takanori Hirose
- Department of Diagnostic Pathology, Hyogo Cancer Center, Hyogo, Japan
| | - Norihiro Teramoto
- Department of Diagnostic Pathology, Shikoku Cancer Center, Matsuyama, Ehime, Japan
| | - Yoshiki Mikami
- Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan
| |
Collapse
|
7
|
Tanaka S, Tokuhara Y, Ariyasu S, Morinishi T, Yamamoto T, Teramoto N, Hirakawa E. Diagnostic Immunocytostaining with Peroxisome Proliferator-Activated Receptor-Gamma in Urine Cytology Samples. Acta Cytol 2023; 68:60-65. [PMID: 38008063 DOI: 10.1159/000535448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Accepted: 11/15/2023] [Indexed: 11/28/2023]
Abstract
INTRODUCTION Urine cytology is a common method for detection of urothelial carcinoma (UC), however, is not high sensitivity. Improvement of the accuracy of cytodiagnosis using immunocytostaining as an auxiliary method is needed. This study aimed to determine the cytodiagnostic usefulness of peroxisome proliferator-activated receptor-gamma (PPAR-γ) immunocytostaining in urine cytology for the detection of UCs, particularly low-grade urothelial carcinomas (LGUC). METHODS PPAR-γ immunocytostaining was performed for 37 UC cases and 26 benign cases. Among the UC cases, 22 cases were of the papillary proliferation type, not including the mixed type comprising both papillary and flat growth. Fifteen LGUC cases of all papillary proliferation types were included. For comparison, the same samples were also immunocytostained for p53 and Ki-67. RESULTS Of the UC cases, 25 of 37 were positive for PPAR-γ, while 24 of the 26 benign cases were PPAR-γ-negative. Regardless of histological grading, 13 of the 22 UC cases with papillary proliferation were PPAR-γ-positive. In particular, PPAR-γ immunocytostaining showed higher sensitivity for LGUC cases than that of the other biomarkers. Regarding LGUC specifically, 4 of 10 cases not identified by primary cytology were detected by PPAR-γ immunocytostaining. CONCLUSION PPAR-γ immunocytostaining enhances the accuracy of urine cytodiagnosis. Furthermore, PPAR-γ is a more useful immunobiomarker in urine cytology than p53 and Ki-67, the commonly used immunobiomarkers for malignant cell detection.
Collapse
Affiliation(s)
- Shinichi Tanaka
- Department of Medical Technology, Kawasaki University of Medical Welfare, Kurashiki, Japan
| | - Yasunori Tokuhara
- Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan
| | - Sanae Ariyasu
- Department of Medical Technology, Kawasaki University of Medical Welfare, Kurashiki, Japan
| | - Tatsuya Morinishi
- Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan
| | - Tamami Yamamoto
- Department of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Japan
| | - Norihiro Teramoto
- Department of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Japan
| | - Eiichiro Hirakawa
- Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Japan
| |
Collapse
|
8
|
Teramoto N, Yamashita N, Ohira Y. Trends in patients' behavior for cancer care and the number of registered cancer cases in Ehime Prefecture during the coronavirus disease pandemic. Jpn J Clin Oncol 2023; 53:922-927. [PMID: 37431159 DOI: 10.1093/jjco/hyad076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 06/20/2023] [Accepted: 06/21/2023] [Indexed: 07/12/2023] Open
Abstract
BACKGROUND The coronavirus disease (COVID-19) pandemic has reduced diagnosed cancer cases worldwide. This study aimed to elucidate the recovery of cancer care from the COVID-19 pandemic in Ehime Prefecture, Japan. METHODS This study collected data from the hospital-based cancer registry (HBCR) as well as the number of outpatients, medical information provision fee payments (MIP2) and second opinion patients (SOP) from the Council of Ehime Cancer Care Hospitals (ECCH). Then cancer care and patient requests for hospital transfers before and during the COVID-19 pandemic were analysed. RESULTS The HBCR from the ECCH comprises >80% of cancer cases in Ehime Prefecture. In 2020, the numbers of all registered cases, first-line treatment cases and cases detected by cancer screening in the HBCR decreased from those in 2018-2019. In 2021, they increased to almost the same levels as those in 2020. In contrast, the number of registered patients that changed hospitals (hospital-change cases) after first-line treatments, patients who lived outside the metropolitan area of Ehime but registered in metropolitan hospitals, MIP2 and SOP remained low in 2021 after decreasing in 2020. Furthermore, the monthly numbers of hospital-change cases, MIP2 and SOP were significantly smaller in 2021 than in 2018-2019 (Wilcoxon rank sum test). CONCLUSIONS The assessed indicators suggest that the decreased patients' behavior to further cancer care had not returned to pre-pandemic levels by 2021. Hence, psychological measures in society to prevent self-restraint in patients and support for the caregivers of the patients who have some problems visiting the hospital are necessary.
Collapse
Affiliation(s)
- Norihiro Teramoto
- Department of Cancer Prevention and Epidemiology, Center for Cancer Research, National Hospital Organization Shikoku Cancer Center
- Department of Pathology, National Hospital Organization Shikoku Cancer Center
- Department of Medical Record Office, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Natsumi Yamashita
- Department of Cancer Prevention and Epidemiology, Center for Cancer Research, National Hospital Organization Shikoku Cancer Center
| | - Yutsuko Ohira
- Department of Medical Record Office, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
9
|
Kobayashi Y, Sugawara Y, Takahata H, Shimizu T, Teramoto N, Ueno T, Ninomiya T. Multiple benign notochordal cell tumors in lung with cystic change. Radiol Case Rep 2023; 18:3117-3121. [PMID: 37416319 PMCID: PMC10319637 DOI: 10.1016/j.radcr.2023.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 06/05/2023] [Accepted: 06/07/2023] [Indexed: 07/08/2023] Open
Abstract
Benign notochordal cell tumor (BNCT) is a benign lesion derived from notochordal cells. Although it is relatively common in intraosseous lesion, pulmonary BNCT is extremely rare. We present a case of 54-year-old male with multiple pulmonary nodules, in which were considered to be metastatic chordomas initially. For 20 months follow-up without any therapy, most of the nodules had no remarkable change but some nodules showed cystic change. We consulted with pathologists specializing in chordoma and the final diagnosis of the nodules was considered as BNCT rather than chordoma. We herein report the case of multiple pulmonary BNCTs with cystic change, comparing with previous reports.
Collapse
Affiliation(s)
- Yusuke Kobayashi
- Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Minamiumemotomachi Kou 160, Matsuyama City, Ehime, 791-0245, Japan
| | - Yoshifumi Sugawara
- Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Minamiumemotomachi Kou 160, Matsuyama City, Ehime, 791-0245, Japan
| | - Hiroyuki Takahata
- Department of Pathology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan
| | - Teruhiko Shimizu
- Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Minamiumemotomachi Kou 160, Matsuyama City, Ehime, 791-0245, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan
| | - Tsuyoshi Ueno
- Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan
| | - Takashi Ninomiya
- Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
10
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Seki T, Kojima A, Okame S, Yamaguchi S, Okamoto A, Tokunaga H, Nishio S, Takei Y, Yokoyama Y, Yoshida M, Teramoto N, Mikami Y, Shimada M, Kigawa J, Takehara K. Poor Treatment Outcomes of Locally Advanced Cervical Adenocarcinoma of Human Papilloma Virus Independent Type, Represented by Gastric Type Adenocarcinoma: A Multi-Center Retrospective Study (Sankai Gynecology Study Group). Cancers (Basel) 2023; 15:cancers15061730. [PMID: 36980616 PMCID: PMC10046139 DOI: 10.3390/cancers15061730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 03/01/2023] [Accepted: 03/03/2023] [Indexed: 03/18/2023] Open
Abstract
The revised World Health Organization classification of cervical cancer divides adenocarcinomas into human papillomavirus-associated (HPVa) and -independent (HPVi) types; the HPVi type is represented by the gastric type. The treatment outcomes of locally advanced adenocarcinoma (LaAC), based on this classification, are understudied. We investigated the outcomes of patients with HPVa and HPVi LaACs. Data for all consecutive patients with stage IB3 to IIIC1 adenocarcinoma who received treatment at 12 institutions throughout Japan between 2004 and 2009 were retrieved to analyze progression-free and overall survival. Central pathological review classified 103 and 48 patients as having HPVa and HPVi tumors, respectively. Usual- (84%) and gastric- (90%) type adenocarcinomas were the most frequent subtypes. Surgery was the primary treatment strategy for most patients. Progression-free and overall survival of patients with HPVi were worse than those of patients with HPVa (p = 0.009 and 0.032, respectively). Subgroup analysis by stage showed that progression-free survival was significantly different for stage IIB. The current surgical treatment strategy for LaACs is less effective for HPVi tumors than for HPVa tumors, especially those in stage IIB.
Collapse
Affiliation(s)
- Toshiyuki Seki
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan; (T.S.)
| | - Atsumi Kojima
- Department of Obstetrics and Gynecology, Iwate Medical University, Yahaba 028-3695, Japan
- Correspondence: ; Tel.: +81-19-613-7111
| | - Shinichi Okame
- Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| | - Satoshi Yamaguchi
- Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi 673-8558, Japan
| | - Aikou Okamoto
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan; (T.S.)
| | - Hideki Tokunaga
- Department of Obstetrics and Gynecology, Tohoku University, Sendai 980-8574, Japan
| | - Shin Nishio
- Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume 830-0011, Japan
| | - Yuji Takei
- Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke 329-0498, Japan
| | - Yoshihito Yokoyama
- Department of Obstetrics and Gynecology, Hirosaki University, Hirosaki 036-8562, Japan
| | - Manabu Yoshida
- Department of Pathology, Matsue City Hospital, Matsue 690-8509, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| | - Yoshiki Mikami
- Department of Diagnostic Pathology, Kumamoto University, Kumamoto 860-8556, Japan
| | - Muneaki Shimada
- Department of Obstetrics and Gynecology, Tohoku University, Sendai 980-8574, Japan
| | | | - Kazuhiro Takehara
- Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| |
Collapse
|
12
|
Nishiwaki N, Mikuriya Y, Takatsu F, Ochiai R, Kakishita T, Kobayashi N, Kobatake T, Hato S, Teramoto N, Nagao M, Fukuda I, Ohta K. Surgical resection of a retroperitoneal liposarcoma producing insulin-like growth factor II: a case report. Surg Case Rep 2023; 9:19. [PMID: 36752872 PMCID: PMC9908783 DOI: 10.1186/s40792-023-01589-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 01/11/2023] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND Tumor-produced high molecular weight insulin-like growth factor-II (big insulin-like growth factor-II) is considered to cause non-islet cell tumor hypoglycemia. This paper presents a case of surgically resected retroperitoneal liposarcoma that produced big insulin-like growth factor-II. CASE PRESENTATION Here, we report the case of a 62-year-old woman who presented with an abdominal mass and hypoglycemia. Non-islet cell tumor hypoglycemia due to retroperitoneal liposarcoma was suspected. After complete resection of the tumor, the patient's hypoglycemia improved and big insulin-like growth factor-II disappeared in the molecular weight analysis of serum insulin-like growth factor-II by western blotting. The patient had no tumor recurrence or reappearance of hypoglycemia 16 months after the operation without any adjuvant therapy. CONCLUSIONS Although insulin-like growth factor-II-producing tumors are generally large and difficult to operate on, surgical resection is currently the most effective and only treatment; thus, it is essential to attempt resection aggressively.
Collapse
Affiliation(s)
- Noriyuki Nishiwaki
- Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken, 791-0280, Japan.
| | - Yoshihiro Mikuriya
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Fumiaki Takatsu
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Ryoji Ochiai
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Tomokazu Kakishita
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Naruyuki Kobayashi
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Takaya Kobatake
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Shinji Hato
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Norihiro Teramoto
- grid.415740.30000 0004 0618 8403Department of Pathology, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| | - Mototsugu Nagao
- grid.410821.e0000 0001 2173 8328Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 113-8603 Japan
| | - Izumi Fukuda
- grid.410821.e0000 0001 2173 8328Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 113-8603 Japan
| | - Koji Ohta
- grid.415740.30000 0004 0618 8403Department of Gastroenterological Surgery, National Hospital Organization, Shikoku Cancer Center, 160, Ko, Minamiumemoto-machi, Matsuyama-shi, Ehime-Ken 791-0280 Japan
| |
Collapse
|
13
|
Tanaka T, Takehara K, Yamashita N, Okazawa-Sakai M, Kuraoka K, Teramoto N, Taguchi K, Yamashiro K, Kato H, Mizunoe T, Suzuki R, Yamamoto D, Ueki A, Saito T. Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma. J Gynecol Oncol 2022; 33:e67. [PMID: 36032025 PMCID: PMC9428302 DOI: 10.3802/jgo.2022.33.e67] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 04/20/2022] [Accepted: 06/12/2022] [Indexed: 11/30/2022] Open
Abstract
Objective To clarify the frequency of deficient mismatch repair (dMMR) in Japanese ovarian cancer patients, we examined microsatellite instability (MSI) status and immunohistochemistry (IHC) subtypes, including endometrioid carcinoma (EMC), clear cell carcinoma (CCC), or a mixture of both (Mix). Methods We registered 390 patients who were diagnosed with EMC/CCC/Mix between 2006 and 2015 and treated at seven participating facilities. For 339 patients confirmed eligible by the Central Pathological Review Board, MSI, IHC, and MutL homolog 1 methylation analyses were conducted. The tissues of patients with Lynch syndrome (LS)-related cancer histories, such as colorectal and endometrial cancer, were also investigated. Results MSI-high (MSI-H) status was observed in 2/217 CCC (0.9%), 10/115 EMC (8.7%), and 1/4 Mix (25%). Additionally, loss of MMR protein expression (LoE-MMR) was observed in 5/219 (2.3%), 16/115 (14.0%), and 1/4 (25%) patients with CCC, EMC, and Mix, respectively. Both MSI-H and LoE-MMR were found significantly more often in EMC (p<0.001). The median (range) ages of patients with MMR expression and LoE-MMR were 54 (30–90) and 46 (22–76) (p=0.002), respectively. In the multivariate analysis, advanced stage and histological type were identified as prognostic factors. Conclusion The dMMR rate for EMC/CCC was similar to that reported in Western countries. In Japan, it is assumed that the dMMR frequency is higher because of the increased proportion of CCC. The deficient mismatch repair (dMMR) rate in Japanese patients is currently unknown. This study determined the frequency of dMMR in Japanese ovarian cancer patients. The dMMR rate was similar to that reported in Western countries. We identified potential criteria for implementing microsatellite instability and immunohistochemistry analyses in Lynch syndrome screening.
Collapse
Affiliation(s)
- Tamaki Tanaka
- Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine, Kida, Japan.,Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Kazuhiro Takehara
- Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
| | - Natsumi Yamashita
- Department of Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Mika Okazawa-Sakai
- Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Kazuya Kuraoka
- Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Kenichi Taguchi
- Department of Pathology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | | | - Hidenori Kato
- Department of Gynecologic Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
| | - Tomoya Mizunoe
- Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan
| | - Rie Suzuki
- Department of Obstetrics and Gynecology, National Defense Medical Collage Hospital, Tokorozawa, Japan
| | - Dan Yamamoto
- Department of Gynecology, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan
| | - Arisa Ueki
- Department of Clinical Genetic Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - Toshiaki Saito
- Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| |
Collapse
|
14
|
Maki Y, Kiriyama Y, Ueno T, Suehisa H, Shigematsu H, Saeki K, Harada D, Kozuki T, Teramoto N, Yamashita M. A Case of Mediastinal Localized Malignant Pleural Mesothelioma Successfully Treated by Chemotherapy and Conversion Surgery. Acta Med Okayama 2022; 76:343-347. [PMID: 35790367 DOI: 10.18926/amo/63746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Localized malignant mesothelioma is a rare disease and little is known about its treatment strategy. We herein report a case of localized malignant pleural mesothelioma that had infiltrated into the anterior mediastinum, which was successfully treated using chemotherapy and conversion surgery. A 63-year-old man with a mediastinal tumor was referred to our hospital. Pathologic analysis of the biopsy specimen showed malignant mesothelioma. Significant tumor shrinkage by cisplatin and pemetrexed was observed and he underwent radical surgery via a median sternotomy. The patient has been disease free for 12 months.
Collapse
Affiliation(s)
- Yuho Maki
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
| | - Yosuke Kiriyama
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
| | - Tsuyoshi Ueno
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
| | - Hiroshi Suehisa
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
| | - Hisayuki Shigematsu
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
| | - Kazuhiko Saeki
- Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center
| | - Daijiro Harada
- Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center
| | - Toshiyuki Kozuki
- Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center
| | - Motohiro Yamashita
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center
| |
Collapse
|
15
|
Tanaka S, Tokuhara Y, Hosokawa S, Ohsaki H, Morinishi T, Yamamoto T, Teramoto N, Hirakawa E. Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma. Mol Clin Oncol 2022; 16:36. [PMID: 34984103 PMCID: PMC8719252 DOI: 10.3892/mco.2021.2469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 10/18/2021] [Indexed: 11/05/2022] Open
Abstract
Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ in non-muscle-invasive urothelial carcinoma. The expression rates of PPAR-γ, p53 and Ki-67 were compared to determine whether PPAR-γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR-γ expression were evaluated in 79 cases of non-muscle-invasive urothelial carcinoma (30 cases of papillary carcinoma low-grade, 30 cases of high-grade and 19 cases of carcinoma in situ) and 30 non-malignant cases. The nuclear overexpression of PPAR-γ was frequently observed in non-muscle-invasive urothelial carcinoma (63/79 cases) but was rarely detected in non-malignant cases (2/30 cases). The histological proliferation types of non-muscle-invasive urothelial carcinoma revealed that PPAR-γ was more frequently overexpressed in papillary carcinoma (54/60 cases) than in carcinoma in situ (9/19 cases). Immunohistochemical staining demonstrated that PPAR-γ was more useful as an immunobiomarker than p53 or Ki-67 (diagnostic odds ratios; 55.13, 16.82 and 11.13, respectively). In summary, this study demonstrated that the expression patterns of PPAR-γ were associated with histological proliferation type and that PPAR-γ was expressed in the nuclei of papillary carcinoma cells. These findings suggested that immunohistochemical staining for PPAR-γ may be used to comprehensively detect non-muscle-invasive urothelial carcinoma.
Collapse
Affiliation(s)
- Shinichi Tanaka
- Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan
- Department of Medical Technology, Kawasaki University of Medical Welfare, Kurashiki, Okayama 701-0193, Japan
| | - Yasunori Tokuhara
- Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan
| | - Sho Hosokawa
- Department of Medical Technology, Ehime Prefectural University of Health Sciences, Iyo, Ehime 791-2101, Japan
| | - Hiroyuki Ohsaki
- Laboratory of Pathology, Department of Medical Technology, Kobe University Graduate School of Health Sciences, Kobe, Hyogo 654-0142, Japan
| | - Tatsuya Morinishi
- Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan
| | - Tamami Yamamoto
- Department of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Ehime 791-0280, Japan
| | - Norihiro Teramoto
- Department of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Ehime 791-0280, Japan
| | - Eiichiro Hirakawa
- Laboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan
| |
Collapse
|
16
|
Takaoka M, Ohsumi S, Miyoshi Y, Takahashi M, Takashima S, Aogi K, Shimizu T, Teramoto N, Yamamoto Y, Okamura M. Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers. Surg Case Rep 2021; 7:228. [PMID: 34674065 PMCID: PMC8531180 DOI: 10.1186/s40792-021-01313-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Accepted: 10/15/2021] [Indexed: 11/10/2022] Open
Abstract
Background Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers aged over 25 years as a secondary prevention of breast cancer. However, breast MRI surveillance is rarely performed in Japan, and only four cases of breast cancer diagnosis triggered by MRI surveillance have been reported. Case presentation At our hospital, MRI triggered the diagnosis of breast cancer in four cancer-free BRCA1/2 mutation carriers. In one of our four cases, although MRI showed only a 3-mm focus, we could diagnose breast cancer by shortening the surveillance interval considering the patient’s high-risk for developing breast cancer. Conclusions Image-guided biopsy, including MRI-guided biopsy, depending on the size of the lesion, and shorter surveillance intervals are useful when there are potentially malignant findings on breast MRI surveillance for cancer-free patients with HBOC.
Collapse
Affiliation(s)
- Megumi Takaoka
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
| | - Shozo Ohsumi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Yuichiro Miyoshi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Mina Takahashi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Seiki Takashima
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Kenjiro Aogi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Teruhiko Shimizu
- Department of Radiology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Yasuko Yamamoto
- Department of Familial Tumor, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| | - Miki Okamura
- Department of Familial Tumor, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan
| |
Collapse
|
17
|
Shidahara T, Ohsumi S, Miyoshi Y, Takahashi M, Takashima S, Aogi K, Teramoto N. A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective. Case Rep Oncol 2021; 14:1632-1637. [PMID: 34950008 PMCID: PMC8647049 DOI: 10.1159/000520357] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Accepted: 10/19/2021] [Indexed: 11/23/2022] Open
Abstract
Chemotherapy is often difficult to treat human epidermal growth factor receptor 2 (HER2)-positive metastatic recurrent breast cancer in the elderly, and no standard treatment has been established at this point. We experienced a case in which trastuzumab (Tmab) + anastrozole (ANA) was ineffective (progressive disease; PD) in elderly HER2-positive breast cancer with postoperative multiple liver metastases, but T-DM1 was significantly effective (complete response; CR), and treatment could be continued safely. An 82-year-old woman was referred to our department with a right breast mass. A close examination revealed right breast cancer cT1bN0M0 cStage I, and total mastectomy and sentinel lymph node biopsy were performed. The postoperative pathological result was pT1bN0M0 pStage I (luminal HER2 type). The patient was elderly and had no adjuvant treatment after the operation. Approximately 2 years after the operation, multiple liver metastases were observed, and treatment with ANA and Tmab was started. Four months later, MRI showed that the number of multiple liver metastases increased. The patient was diagnosed with PD, and the anti-HER2 drug was changed from trastuzumab to trastuzumab emtansine (T-DM1). The dose was reduced due to vomiting (grade 3). Two months later, MRI showed that the multiple liver metastases shrank and became obscure after 5 months. After that, T-DM1 was continued, and the disease did not worsen. In elderly people with difficulty in administering chemotherapy, T-DM1 may have a safe and sufficient therapeutic effect by adjusting the dose and managing side effects appropriately.
Collapse
Affiliation(s)
- Tomohiro Shidahara
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Shozo Ohsumi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Yuichiro Miyoshi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Mina Takahashi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Seiki Takashima
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Kenjiro Aogi
- Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Norihiro Teramoto
- Departments of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
18
|
Matsumoto H, Nasu K, Shikama A, Shiozaki T, Futagami M, Kai K, Mori T, Yano M, Yamada T, Teramoto N. Pathological processes and pretreatment cytologic diagnosis of neuroendocrine carcinoma of the endometrium: addendum report of the Kansai Clinical Oncology Group/Intergroup study in Japan. Med Mol Morphol 2021; 54:237-244. [PMID: 33934220 DOI: 10.1007/s00795-021-00288-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 04/09/2021] [Indexed: 11/28/2022]
Abstract
A previous retrospective study of a neuroendocrine carcinoma of the endometrium including 42 cases employed a central pathologic review to ensure the reliability of the findings. However, the pathological processes were not described in detail. In this study, we further analyzed these processes and the results of pretreatment endometrial cytology of neuroendocrine carcinoma. Of the 65 patients from 18 institutions registered in the study, 42 (64.6%) were diagnosed with neuroendocrine carcinoma of the endometrium based on the central pathological review. Thirteen of the 23 excluded cases conflicted from their original diagnoses: 5 (38.5%) were diagnosed with endometrioid adenocarcinoma, 5 (38.5%) with undifferentiated carcinoma, and 3 (23.1%) with carcinosarcoma. Immunohistochemical staining led to a change in diagnosis for 8 (61.5%) of the 13 cases. Pretreatment endometrial cytology was examined in 38 (90.5%) cases; 34 (89.5%) of these 38 cases were found, or suspected, to be positive. To ensure the selection of appropriate therapy and keeping patients correctly informed, it is important to distinguish neuroendocrine carcinoma from other similar histologic types. Endometrial cytology may help in the early detection of this disease.
Collapse
Affiliation(s)
- Harunobu Matsumoto
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita, 8795593, Japan.
| | - Kaei Nasu
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita, 8795593, Japan
| | - Ayumi Shikama
- Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Takaya Shiozaki
- Division of Gynecology, Hyogo Cancer Center, Akashi-shi, Hyogo, Japan
| | - Masayuki Futagami
- Department of Obstetrics and Gynecology, Hirosaki University, Hirosaki-shi, Aomori, Japan
| | - Kentaro Kai
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita, 8795593, Japan
| | - Taisuke Mori
- Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto, Japan
| | - Mitsutake Yano
- Division of Pathology, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
| | - Takashi Yamada
- Department of Pathology, Osaka Medical College, Takatsuki-shi, Osaka, Japan
| | - Norihiro Teramoto
- Division of Pathology, Shikoku Cancer Center, Matsuyama-shi, Ehime, Japan
| |
Collapse
|
19
|
Kinoshita I, Kohashi K, Yamamoto H, Yamada Y, Inoue T, Higaki K, Teramoto N, Oshiro Y, Nakashima Y, Oda Y. Myxoepithelioid tumour with chordoid features: a clinicopathological, immunohistochemical and genetic study of 14 cases of SMARCB1/INI1-deficient soft-tissue neoplasm. Histopathology 2021; 79:629-641. [PMID: 33932047 DOI: 10.1111/his.14393] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/21/2021] [Accepted: 04/27/2021] [Indexed: 11/27/2022]
Abstract
AIMS Complete loss of SMARCB1/INI1 in soft-tissue tumours such as malignant rhabdoid tumour, epithelioid sarcoma, myoepithelial tumour of soft tissue and extraskeletal myxoid chondrosarcoma is often associated with high-grade malignancy and poor prognosis. The diagnosis is sometimes challenging, owing to histological similarities, so careful differential diagnosis is required. Therefore, soft-tissue tumours with complete SMARCB1/INI1 loss could potentially include an unknown entity. METHODS AND RESULTS We analysed 160 cases of SMARCB1/INI1-deficient soft-tissue tumour, and found 14 cases that were not classifiable into already existing categories and had common clinical and histological features. These involved two male and 12 female patients, ranging in age from 20 years to 61 years. The tumours were located in the the puboinguinal region (n = 13) and pelvic cavity (n = 1). Histologically, the tumours showed relatively uniform epithelioid to spindle-shaped cells with myxoid stroma. All tumours showed immunoreactivity for brachyury, epithelial membrane antigen, and progesterone receptor, and 12 of 14 cases did so for oestrogen receptor. Variable positive staining for α-smooth muscle actin, S100 and glial fibrillary acidic protein (GFAP) was seen. NR4A3 and EWSR1 gene rearrangements were not detected in 13 and 11 examined cases, respectively. Clinical follow-up data for the 14 patients showed that 13 were alive without disease and one had been lost to follow-up; four patients developed local recurrence and/or metastases. CONCLUSION The designation 'myxoepithelioid tumour with choroid features' (METC) was proposed as a tumour with intermediate malignancy controllable with appropriate treatment, including the entity of myoepithelioma-like tumour of the vulvar region. METC represents a novel and independent subset that is histologically, biologically and clinically distinct from already existing SMARCB1/INI1-deficient soft-tissue tumours.
Collapse
Affiliation(s)
- Izumi Kinoshita
- Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kenichi Kohashi
- Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Hidetaka Yamamoto
- Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yuichi Yamada
- Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Takeshi Inoue
- Department of Pathology, Osaka City General Hospital, Osaka, Japan
| | - Koichi Higaki
- Department of Diagnostic Pathology, St Mary's Hospital, Fukuoka, Japan
| | - Norihiro Teramoto
- Department of Pathology and Clinical Research, National Hospital Organisation Shikoku Cancer Centre, Matsuyama, Ehime, Japan
| | - Yumi Oshiro
- Department of Pathology, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan
| | - Yasuharu Nakashima
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yoshinao Oda
- Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
20
|
Kai K, Nasu K, Nishida H, Daa T, Shikama A, Shiozaki T, Kurakazu M, Yano M, Imamura Y, Tokunaga H, Tasaki K, Iida Y, Yamada Y, Morisawa H, Nakagawa S, Fujimoto E, Tsuruta T, Matsumoto H, Arakawa A, Nonaka M, Takano H, Ushiwaka T, Mori T, Ito K, Motohashi T, Teramoto N, Yamada T. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study. Neuroendocrinology 2021; 111:320-329. [PMID: 32097950 DOI: 10.1159/000506743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2019] [Accepted: 02/21/2020] [Indexed: 11/19/2022]
Abstract
BACKGROUND In 2014, the World Health Organization (WHO) released a classification system introducing neuroendocrine neoplasms (NENs) of the female reproductive tract, excluding the ovaries. This study aimed to evaluate whether retrospective adaption of the gastroenteropancreatic (GEP)-NEN classification is feasible for ovarian NENs (O-NENs) and correlates with prognosis. METHODS Sixty-eight patients diagnosed with carcinoid, small cell carcinoma (pulmonary type), paraganglioma, non-small/large cell neuroendocrine carcinoma (NEC), mixed NEC, or undifferentiated carcinomas at 20 institutions in Japan were included in this retrospective cross-sectional study. We identified O-NENs through central pathological review using a common slide set, followed by reclassification according to WHO 2010 guidelines for GEP-NENs. A proportional hazards model was used to assess the association of prognostic factors (age, stage, performance status, histology, and residual disease) with overall survival (OS) and progression-free survival (PFS). RESULTS Of the 68 enrolled patients, 48 were eligible for analysis. All carcinoids (n = 32) were reclassified as NET G1/G2, whereas 14 of 16 carcinomas were reclassified as NEC/mixed adeno-NEC (MANEC) (Fisher's exact test; p < 0.01). The OS/PFS was 49.0/42.5 months and 6.5/3.9 months for NET G1/G2 and NEC/MANEC, respectively. Histology revealed that NEC/MANEC was associated with increased risk of death (HR = 48.0; 95% CI, 3.93-586; p < 0.01) and disease progression (HR = 51.6; 95% CI, 5.54-480; p < 0.01). CONCLUSION Retrospective adaption of GEP-NEN classification to O-NENs is feasible and correlates well with the prognosis of O-NENs. This classification could be introduced for ovarian tumors.
Collapse
Affiliation(s)
- Kentaro Kai
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Yufu, Japan,
| | - Kaei Nasu
- Division of Obstetrics and Gynecology, Support System for Community Medicine, Faculty of Medicine, Oita University, Yufu, Japan
| | - Haruto Nishida
- Department of Diagnostic Pathology, Faculty of Medicine, Oita University, Yufu, Japan
| | - Tsutomu Daa
- Department of Diagnostic Pathology, Faculty of Medicine, Oita University, Yufu, Japan
| | - Ayumi Shikama
- Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba, Japan
| | | | - Masamitsu Kurakazu
- Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Mitsutake Yano
- Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Japan
| | - Yuko Imamura
- Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - Hideki Tokunaga
- Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Kazuto Tasaki
- Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan
| | - Yasushi Iida
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Minato, Japan
| | - Yuki Yamada
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan
| | - Hiroyuki Morisawa
- Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke, Japan
| | - Satoshi Nakagawa
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Etsuko Fujimoto
- Department of Gynecologic oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Tomohiko Tsuruta
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Harunobu Matsumoto
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Yufu, Japan
| | - Atsushi Arakawa
- Department of Obstetrics and Gynecology, Nagoya City University Graduate School of Medicine, Nagoya, Japan
| | - Michiko Nonaka
- Department of Obstetrics and Gynecology, Faculty of MedicineTottori University, Yonago, Japan
| | - Hirokuni Takano
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Minato, Japan
| | - Takashi Ushiwaka
- Department of Obstetrics and Gynecology, Kochi University Kochi Medical School, Nankoku, Japan
| | - Taisuke Mori
- Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Kimihiko Ito
- Chairperson, Kansai Clinical Oncology Group (KCOG), Osaka, Japan
| | - Takashi Motohashi
- Division Director of Gynecology, Kansai Clinical Oncology Group (KCOG), Osaka, Japan
| | - Norihiro Teramoto
- Division head of Cancer Prevention and Epidemiology, Center for Clinical Research, Shikoku Cancer Center, Matsuyama, Japan
| | - Takashi Yamada
- Department of Pathology, Osaka Medical College, Takatsuki, Japan
| |
Collapse
|
21
|
Matsumoto H, Shimokawa M, Nasu K, Shikama A, Shiozaki T, Futagami M, Kai K, Nagano H, Mori T, Yano M, Sugino N, Fujimoto E, Yoshioka N, Nakagawa S, Shimada M, Tokunaga H, Yamada Y, Tsuruta T, Tasaki K, Nishikawa R, Kuji S, Motohashi T, Ito K, Yamada T, Teramoto N. Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan. J Gynecol Oncol 2020; 30:e103. [PMID: 31576694 PMCID: PMC6779616 DOI: 10.3802/jgo.2019.30.e103] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 05/04/2019] [Accepted: 06/09/2019] [Indexed: 12/19/2022] Open
Abstract
Objective We conducted a retrospective, multi-institutional, collaborative study to accumulate cases of neuroendocrine carcinoma of the endometrium, to clarify its clinicopathologic features, treatment, prognosis and prognostic factors to collate findings to establish future individualized treatment regimens. To our knowledge, this is the largest case study and the first study to statistically analyze the prognosis of this disease. Methods At medical institutions participating in the Kansai Clinical Oncology Group/Intergroup, cases diagnosed at a central pathologic review as neuroendocrine carcinoma of the endometrium between 1995 and 2014 were enrolled. We retrospectively analyzed the clinicopathologic features, treatment, prognosis and prognostic factors of this disease. Results A total of 65 cases were registered from 18 medical institutions in Japan. Of these, 42 (64.6%) cases were diagnosed as neuroendocrine carcinoma of the endometrium based on the central pathological review and thus included in the study. Advanced International Federation of Gynecology and Obstetrics stages (stage III and IV) and pure type small cell neuroendocrine carcinoma cases had a significantly worse prognosis. Upon multivariate analysis, only histologic subtypes and surgery were significant prognostic factors. Pure type cases had a significantly worse prognosis compared to mixed type cases and complete surgery cases had a significantly better prognosis compared to cases with no or incomplete surgery. Conclusion Our findings suggest that complete surgery improves the prognosis of neuroendocrine carcinoma of the endometrium. Even among cases with advanced disease stages, if complete surgery is expected to be achieved, clinicians should consider curative surgery to improve the prognosis of neuroendocrine carcinoma of the endometrium.
Collapse
Affiliation(s)
- Harunobu Matsumoto
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan.
| | - Mototsugu Shimokawa
- Cancer Biostatistics Laboratory, Clinical Research Institute, National Kyusyu Cancer Center, Fukuoka, Japan
| | - Kaei Nasu
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan.,Division of Obstetrics and Gynecology, Support System for Regional Medicine, Oita University, Oita, Japan
| | - Ayumi Shikama
- Department of Obstetrics and Gynecology, University of Tsukuba, Ibaraki, Japan
| | | | - Masayuki Futagami
- Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Aomori, Japan
| | - Kentaro Kai
- Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan
| | - Hiroaki Nagano
- Department of Obstetrics and Gynecology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
| | - Taisuke Mori
- Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Mitsutake Yano
- Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Norihiro Sugino
- Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| | - Etsuko Fujimoto
- Division of Gynecology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| | - Norihito Yoshioka
- Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan
| | - Satoshi Nakagawa
- Department of Obstetrics and Gynecology, Osaka University, Osaka, Japan
| | - Muneaki Shimada
- Department of Obstetrics and Gynecology, Tottori University, Tottori, Japan
| | - Hideki Tokunaga
- Department of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan
| | - Yuki Yamada
- Department of Obstetrics and Gynecology, Nara Medical University, Nara, Japan
| | - Tomohiko Tsuruta
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Hyogo, Japan
| | - Kazuto Tasaki
- Department of Obstetrics and Gynecology, Kurume University, Fukuoka, Japan
| | - Ryutaro Nishikawa
- Department of Obstetrics and Gynecology, Nagoya City University, Aichi, Japan
| | - Shiho Kuji
- Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan
| | - Takashi Motohashi
- Department of Obstetrics and Gynecology, Kuwana City Medical Center, Mie, Japan
| | - Kimihiko Ito
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Hyogo, Japan
| | - Takashi Yamada
- Department of Pathology, Osaka Medical College, Osaka, Japan
| | - Norihiro Teramoto
- Division of Pathology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
| |
Collapse
|
22
|
Ohsawa M, Mikuriya Y, Ohta K, Tanada M, Yamamoto N, Teramoto N, Kiyono M, Sugihara S. Rare pancreatic metastasis of undifferentiated pleomorphic sarcoma originating from the pelvis: A case report. Int J Surg Case Rep 2020; 68:140-144. [PMID: 32155585 PMCID: PMC7063109 DOI: 10.1016/j.ijscr.2020.02.041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2020] [Accepted: 02/18/2020] [Indexed: 01/19/2023] Open
Abstract
INTRODUCTION Undifferentiated pleomorphic sarcoma (UPS) is a reclassification of malignant fibrous histiocytoma by the World Health Organization in 2002. UPS, the most common soft tissue sarcoma reported in adults, mostly recurs as lung disease. Pancreatic metastasis of UPS is extremely rare. We present a rare case of pelvic UPS with pancreatic metastasis. PRESENTATION OF CASE A 69-year-old man was identified as having mediastinal lymphadenopathy on follow-up computed tomography (CT), 2 years after undergoing surgery for gastric adenocarcinoma (pT4aN3M0/IIIC). Subsequent positron emission tomography-CT (PET/CT) indicated pelvic lesions and magnetic resonance imaging (MRI) showed multiple tumors of the left pubis and femur. Histopathology of diagnostic thoracoscopic lymph node dissection and CT-guided needle biopsy of the left pubic lesion showed UPS. Systemic chemotherapy and targeted molecular therapy reduced multiple pelvic and metastatic tumors. Left pubic primary lesion contraction was achieved with intensity-modulated radiation therapy. CT performed 4 years after treatment initiation showed a 40-mm pancreatic head mass. Lesions other than the pancreatic tumor were in remission, and a pancreatoduodenectomy was performed. Histological analysis confirmed pancreatic metastasis of anaplastic pleomorphic sarcoma. DISCUSSION Reports of pelvic UPS with pancreatic metastasis, as that of the present case, are extremely rare. UPS is malignant potential tumor, and complete excision is the first treatment option, while the usefulness of chemotherapy or radiation therapy remains uncertain. CONCLUSIONS Complete resection is vital for local control in pancreatic metastasis of UPS. Sites of recurrence are rare; hence, patients must be carefully followed up.
Collapse
Affiliation(s)
- Manato Ohsawa
- Department of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan.
| | - Yoshihiro Mikuriya
- Department of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Koji Ohta
- Department of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Minoru Tanada
- Department of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Noriaki Yamamoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Masahiro Kiyono
- Department of Orthopedic Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Shinsuke Sugihara
- Department of Orthopedic Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| |
Collapse
|
23
|
Takehara K, Yamashita N, Watanabe R, Teramoto N, Tsuda H, Motohashi T, Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Saito T. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma. Gynecol Oncol 2020; 157:115-120. [PMID: 31983515 DOI: 10.1016/j.ygyno.2020.01.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 12/31/2019] [Accepted: 01/13/2020] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Uterine leiomyosarcoma (uLMS) is a rare gynecologic malignancy for which the currently available treatments do not consistently provide long-term disease control. This study aimed to reveal the current clinical status of uLMS to support future clinical trials. METHODS This study enrolled patients with uLMS treated at 53 Japanese institutions from 2000 to 2012. Central pathological review (CPR) was performed. All cases were confirmed by CPR, and epidemiological features, treatment, and prognosis were analyzed statistically. RESULTS A total of 307 patients were enrolled. A diagnosis of uLMS was confirmed in 266 patients (86.6%) of patients after CPR, of whom data for 259 were analyzed. Of these, 186 (71.8%) patients underwent complete gross resection as primary therapy. Ninety-eight patients received no additional adjuvant therapy, while docetaxel and gemcitabine was the most frequent regimen among 155 patients treated with adjuvant chemotherapy. In all cases, the median overall survival (OS) was 44.2 months. Multivariate analyses of prognostic factors in all cases identified stage III and IV disease, high serum lactate dehydrogenase level, and menopausal status as poor prognostic factors. However, in stage I cases, high serum lactate dehydrogenase level and no adjuvant treatment were identified as poor prognostic factors. The 5-year OS of patients with stage I uLMS treated with adjuvant chemotherapy was significantly better than that of those without adjuvant treatment (67.8% vs 46.7%, P = 0.0461). CONCLUSIONS Despite complete removal of the primary lesion, the clinical course of patients with uLMS was poor due to recurrence of distant metastasis. The application of a suitable biomarker and effective adjuvant chemotherapy are required to improve the prognosis of patients with uLMS.
Collapse
Affiliation(s)
- Kazuhiro Takehara
- Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemotomachi, Matsuyama, Japan.
| | - Natsumi Yamashita
- Department of Clinical Research Center, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemotomachi, Matsuyama, Japan.
| | - Reiko Watanabe
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Japan.
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemotomachi, Matsuyama, Japan.
| | - Hitoshi Tsuda
- Department of Basic Pathology, National Defense Medical College Hospital, 3-2 Namiki, Tokorozawa, Japan.
| | - Takashi Motohashi
- Department of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, 8-1Kawada-cho, Shinjuku-ku, Tokyo, Japan.
| | - Kenichi Harano
- Department of Experimental Therapeutics/Breast Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Japan.
| | - Toru Nakanishi
- Department of Obstetrics and Gynecology, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, Japan.
| | - Hideki Tokunaga
- Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-cho Aoba-ku, Sendai, Japan.
| | - Nobuyuki Susumu
- Department of Obstetrics and Gynecology, International University of Health and Welfare, 4-3, Kozunomori, Narita, Japan.
| | - Yutaka Ueda
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.
| | - Yoshihito Yokoyama
- Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 53 Honcho, Hirosaki, Japan.
| | - Toshiaki Saito
- Department of Gynecology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Nodame Minami-ku, Fukuoka, Japan.
| |
Collapse
|
24
|
Ohsawa M, Kagawa T, Ochiai R, Kobayashi N, Hato S, Nozaki I, Takahata H, Teramoto N, Kobatake T. Rare squamous cell carcinoma arising from a presacral epidermoid cyst: A case report. Int J Surg Case Rep 2019; 66:283-287. [PMID: 31884265 PMCID: PMC6939061 DOI: 10.1016/j.ijscr.2019.12.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 12/09/2019] [Accepted: 12/12/2019] [Indexed: 11/17/2022] Open
Abstract
Presacral epidermoid cysts are extremely rare and require further study. Thorough preoperative imaging evaluation is important for complete resection. Multidisciplinary treatments may be effective. Presacral epidermoid cysts may be malignant.
Introduction Presacral epidermoid cysts are uncommon, usually benign cysts caused by developmental abnormalities in the fetal period. We present a rare case of squamous cell carcinoma arising from a presacral epidermoid cyst. Presentation of case A 59-year-old woman complained of tenesmus and discomfort in the buttocks. Computed tomography revealed a 50-mm well-defined cystic mass in the presacrum and a 70-mm solid mass extending from the cyst into the rectum, vagina, and left sciatic spine. On T1-weighted magnetic resonance images, the cyst was unilocular and the mass was marginated with low intensity. On T2-weighted images, the mass had high intensity. A malignant presacral developmental cyst was diagnosed, without obvious metastasis. Using abdominal and parasacral approaches, Hartmann’s operation was performed with multiorgan resection, including the sacrum, coccyx, left sciatic spine, internal obturator muscle, rectum, and uterine appendage. Histopathology of the excised specimen revealed a squamous cell carcinoma originating from the presacral epidermoid cyst. Discussion Reports of malignant transformation of epidermoid cysts in the presacral space, as in the present case, are extremely rare. Because of their unusual location and slow growth, epidermoid cysts tend to remain asymptomatic. Because the patient had a malignant tumor with suspected invasion of adjacent organs, combination surgery was selected. Conclusion Although further research is required, presacral epidermoid cysts are extremely rare and may be malignant. Thorough preoperative image evaluation is crucial for complete resection.
Collapse
Affiliation(s)
- Manato Ohsawa
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan.
| | - Tetsuya Kagawa
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Ryoji Ochiai
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Naruyuki Kobayashi
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Shinji Hato
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Isao Nozaki
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Hiroyuki Takahata
- Departments of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Norihiro Teramoto
- Departments of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| | - Takaya Kobatake
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center, 160 Minamiumemotomachikou, Matsuyama-shi, Ehime, Japan
| |
Collapse
|
25
|
Kawasaki T, Hasebe T, Oiwa M, Sugiyama K, Muramatsu C, Ueda S, Osaki A, Ichikawa J, Teramoto N, Hoshida Y. Invasive carcinoma with neuroendocrine differentiation of the breast showing triple negative, large and basal cell-like features. Pathol Int 2019; 69:502-504. [PMID: 31338942 DOI: 10.1111/pin.12832] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Tomonori Kawasaki
- Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.,Clinical Research Center, National Hospital Organization (NHO), Nagoya Medical Center, Aichi, Japan
| | - Takahiro Hasebe
- Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Mikinao Oiwa
- Clinical Research Center, National Hospital Organization (NHO), Nagoya Medical Center, Aichi, Japan
| | - Keiji Sugiyama
- Clinical Research Center, National Hospital Organization (NHO), Nagoya Medical Center, Aichi, Japan
| | | | - Shigeto Ueda
- Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Akihiko Osaki
- Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Jiro Ichikawa
- Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Japan
| | - Norihiro Teramoto
- Department of Pathology, NHO, Shikoku Cancer Center, Matsuyama, Japan
| | - Yoshihiko Hoshida
- Department of Pathology, NHO, Osaka Minami Medical Center, Kawachinagano, Japan
| |
Collapse
|
26
|
Takehara K, Yamashita N, Motohashi T, Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Watanabe Y, Watanabe R, Teramoto N, Tsuda H, Saito T. Prognostic factors in patients with uterine leiomyosarcoma: A multiinstitutional retrospective study from the Japanese gynecologic oncology group. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Ueno T, Maki Y, Sugimoto R, Yamashita M, Nakata K, Sugawara Y, Nishimura R, Teramoto N. Surgical outcomes in 13 patients with bronchopulmonary carcinoid tumors including one recurrent oncocytic carcinoid tumor. Gen Thorac Cardiovasc Surg 2018; 67:486-489. [PMID: 29971648 DOI: 10.1007/s11748-018-0967-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 06/27/2018] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Bronchopulmonary carcinoids are low-grade tumors for which the standard treatment is surgical resection. We retrospectively evaluated the surgical outcomes. METHODS Thirteen patients underwent surgical resection for them at our institution between January 2005 and December 2016. We collected their clinicopathologic data to evaluate surgical outcomes. RESULTS The 13 patients comprised seven men and six women. Complete resection was performed in all cases. All the tumors were typical carcinoids, including one oncocytic carcinoid which showed highest fluorodeoxyglucose (FDG) uptake (SUVmax 45.7). The 5-year overall survival rates were 100%. The only patient with oncocytic carcinoid developed recurrence of liver metastasis 49 months after the primary lung resection. The metastasis showed low FDG uptake (SUVmax 2.8) and its histology was typical carcinoid and not oncocytic carcinoid. CONCLUSION Surgical outcomes in our patients were favorable. In oncocytic carcinoid, metastatic site may have a radiologic and histologic appearance different from the primary tumor.
Collapse
Affiliation(s)
- Tsuyoshi Ueno
- Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center, 160 Minami-Umemoto, Matsuyama, 791-0280, Japan.
| | - Yuho Maki
- Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center, 160 Minami-Umemoto, Matsuyama, 791-0280, Japan
| | - Ryujiro Sugimoto
- Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center, 160 Minami-Umemoto, Matsuyama, 791-0280, Japan
| | - Motohiro Yamashita
- Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center, 160 Minami-Umemoto, Matsuyama, 791-0280, Japan
| | - Kentaro Nakata
- Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center, 160 Minami-Umemoto, Matsuyama, 791-0280, Japan
| | - Yoshifumi Sugawara
- Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan
| | - Rieko Nishimura
- Department of Pathology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
28
|
Tsukamoto Y, Takahata H, Teramoto N, Nishimura R, Hato S, Nozaki I, Matsuo S, Hirota S. Primary gastric low-grade fibromyxoid sarcoma with FUS-CREB3L1 fusion – A hitherto undescribed origin of Evans tumor. Human Pathology: Case Reports 2018. [DOI: 10.1016/j.ehpc.2017.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
29
|
Takiguchi S, Inoue K, Matsusue K, Furukawa M, Teramoto N, Iguchi H. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer. Int J Oncol 2017; 51:184-192. [PMID: 28498406 DOI: 10.3892/ijo.2017.3992] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 04/18/2017] [Indexed: 11/06/2022] Open
Abstract
Peritoneal dissemination is a frequent occurrence in pancreatic cancer, which is associated with a poor prognosis. MET is associated with the progression of pancreatic cancer; therefore, we evaluated the effect of a MET inhibitor, crizotinib, on peritoneal dissemination of pancreatic cancer. Crizotinib inhibited the growth of 8 pancreatic cancer cell lines with the IC50 ranging from 1.4 to 4.3 µM. Invasion of the pancreatic cancer cell line Suit-2, was suppressed in vitro at a concentration of 1.0 µM, which is sufficient for the inhibition of MET phosphorylation. This effect on cell invasion was also recapitulated by the reduction of MET expression in Suit-2 with siRNA. Crizotinib also inhibited RhoA activation in addition to MET phosphorylation. We further evaluated the effect of crizotinib on peritoneal dissemination of pancreatic cancer in vivo. Crizotinib reduced tumor burden and ascites accumulation due to development of peritoneal dissemination after inoculation of Suit-2. Taken together, crizotinib may be a potent drug for treating peritoneal dissemination of pancreatic cancer by inhibiting cancer cell proliferation and invasion, at least in part through the suppression of HGF/MET signaling and RhoA activation.
Collapse
Affiliation(s)
- Soichi Takiguchi
- Clinical Research Institute, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Kazuko Inoue
- Clinical Research Institute, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Kimihiko Matsusue
- Department of Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
| | - Masayuki Furukawa
- Department of Hepato-Biliary-Pancreatology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Norihiro Teramoto
- Division of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| | - Haruo Iguchi
- Clinical Research Institute, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| |
Collapse
|
30
|
Roma AA, Mistretta TA, Diaz De Vivar A, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Teramoto N, Ali-Fehmi R, Barbuto D, Rutgers JKL, Silva EG. New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome. Gynecol Oncol 2016; 141:36-42. [PMID: 27016227 DOI: 10.1016/j.ygyno.2016.02.028] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 01/18/2016] [Accepted: 02/21/2016] [Indexed: 11/26/2022]
Abstract
We present a recently introduced three tier pattern-based histopathologic system to stratify endocervical adenocarcinoma (EAC) that better correlates with lymph node (LN) metastases than FIGO staging alone, and has the advantage of safely predicting node-negative disease in a large proportion of EAC patients. The system consists of stratifying EAC into one of three patterns: pattern A tumors characterized by well-demarcated glands frequently forming clusters or groups with relative lobular architecture and lacking destructive stromal invasion or lymphovascular invasion (LVI), pattern B tumors demonstrating localized destructive invasion (small clusters or individual tumor cells within desmoplastic stroma often arising from pattern A glands), and pattern C tumors with diffusely infiltrative glands and associated desmoplastic response. Three hundred and fifty-two cases were included; mean follow-up 52.8 months. Seventy-three patients (21%) had pattern A tumors; all were stage I and there were no LN metastases or recurrences. Pattern B was seen in 90 tumors (26%); all were stage I and LVI was seen in 24 cases (26.6%). Nodal disease was found in only 4 (4.4%) pattern B tumors (one IA2, two IB1, one IB not further specified (NOS)), each of which showed LVI. Pattern C was found in 189 cases (54%), 117 had LVI (61.9%) and 17% were stage II or greater. Forty-five (23.8%) patients showed LN metastases (one IA1, 14 IB1, 5 IB2, 5 IB NOS, 11 II, 5 III and 4 IV) and recurrences were recorded in 41 (21.7%) patients. This new risk stratification system identifies a subset of stage I patients with essentially no risk of nodal disease, suggesting that patients with pattern A tumors can be spared lymphadenectomy. Patients with pattern B tumors rarely present with LN metastases, and sentinel LN examination could potentially identify these patients. Surgical treatment with nodal resection is justified in patients with pattern C tumors.
Collapse
Affiliation(s)
| | - Toni-Ann Mistretta
- Baylor College of Medicine, Texas Children's Hospital Pavilion for Women, Houston, TX, USA
| | - Andrea Diaz De Vivar
- Baylor College of Medicine, Texas Children's Hospital Pavilion for Women, Houston, TX, USA
| | - Kay J Park
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Golnar Rasty
- University Health Network, University of Toronto, Toronto, Canada
| | | | | | - Sung R Hong
- Cheil General Hospital & Women's Healthcare Center, Dankook University, Seoul, Republic of Korea
| | | | | | | | | | - Elvio G Silva
- Cedars-Sinai Medical Center, Los Angeles, CA, USA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
31
|
Abstract
Background: The aim of this study was to examine the histological outcome and potential therapeutic benefit of second transurethral resection (TUR) for high-grade T1 bladder cancer. Patients and Methods: The subjects were 171 patients who underwent initial TUR between January 1993 and December 2013, and were diagnosed with high-grade T1 bladder cancer. Second TUR was performed within 4–6 weeks after the initial resection. Intravesical recurrence, invasive intravesical recurrence, and disease-free, progression-free, and overall survival were examined between second TUR group and no second TUR group. Results: Of the 171 patients, 79 (46.2%) underwent second TUR. Histological findings from second TUR were no cancer in 33 (41.8%), carcinoma in situ in 18 (22.9%), Ta in 15 (19.0%), T1 in 12 (15.2%), and muscle invasive bladder cancer (T2) in 1 case (1.3%). The 5- and 10-year intravesical recurrence-free survival rates were 72.0% and 57.4%, respectively, and the disease-free survival rates at these times were 69.7% and 49.6%, respectively. Second TUR had no influence on intravesical recurrence, regardless of the use of Bacillus Calmette–Guerin (BCG) therapy. No BCG therapy and recurrent cancer were significantly associated with intravesical recurrence in multivariate analysis. Recurrent cancer was also a significant risk factor for invasive intravesical recurrence. BCG therapy significantly improved disease-free survival. Second TUR was a significant factor in overall survival. In the histological results for second TUR, no cancer and Tis cases had reduced intravesical recurrence compared to Ta and T1 cases. Conclusion: Second TUR allows more accurate staging and pT0 cases in second TUR have a better outcome, indicating a possible therapeutic benefit of the procedure.
Collapse
Affiliation(s)
- Katsuyoshi Hashine
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Takehiro Ide
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Takeshi Nakashima
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Tadanori Hosokawa
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Iku Ninomiya
- Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Norihiro Teramoto
- Department of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
32
|
Suehisa H, Ueno T, Sawada S, Yamashita M, Teramoto N. A Case of Mediastinal Cystic Lymphangioma. Acta Med Okayama 2015; 69:361-3. [PMID: 26690247 DOI: 10.18926/amo/53911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
A 35-year-old Japanese man's routine chest radiography revealed an abnormal opacity. Chest computed tomography and magnetic resonance imaging showed a 5.5 cm in dia. cystic tumor located at the left anterior mediastinum. The tumor was suspected to be an asymptomatic thymic cyst, and we chose observation for the tumor. At the 3-year follow up, the cystic tumor had gradually enlarged to 7.5 cm in dia. and we thus performed a surgical resection via left video-assisted thoracic surgery. An immunohistochemical analysis showed that the cystic tumor was not a thymic cyst but rather a mediastinal cystic lymphangioma. Mediastinal cystic lymphangiomas are very rare, and they are difficult to diagnose preoperatively. Complete surgical resection is proposed for the treatment of such tumors.
Collapse
Affiliation(s)
- Hiroshi Suehisa
- Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280,
| | | | | | | | | |
Collapse
|
33
|
Yamamoto Y, Takehara K, Okame S, Komatsu M, Shiroyama Y, Yokoyama T, Tanaka S, Sato M, Nishimura R, Teramoto N. A case of ependymoma arising from the peritoneum. Int Cancer Conf J 2015; 5:121-125. [PMID: 31149438 DOI: 10.1007/s13691-015-0240-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 12/07/2015] [Indexed: 10/22/2022] Open
Abstract
Ependymoma arising from the peritoneum is extremely rare. We present the case of a 23-year-old woman who underwent urgent laparoscopic surgery because of a pelvic mass and intraperitoneal bleeding. Although peritoneal carcinoma was suspected, pathological re-examination revealed ependymoma with a perivascular pseudorosette and positive for glial fibrillary acidic protein. Residual tumor extraction indicated that the ependymoma had developed from the peritoneum. This case highlights the need to consider ependymoma as a potential diagnosis in young women with suspected ovarian or peritoneal cancer.
Collapse
Affiliation(s)
- Yasuko Yamamoto
- 1Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan.,2Department of Obstetrics and Gynecology, Graduate School of Biomedical Science, Hiroshima University, Kasumi 1-2-3 Minami-ku, Hiroshima, 734-8551 Japan
| | - Kazuhiro Takehara
- 1Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Shinichi Okame
- 1Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Masaaki Komatsu
- 1Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Yuko Shiroyama
- 1Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Takashi Yokoyama
- 1Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Shinichi Tanaka
- 3Department of Clinical Laboratory, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Masakazu Sato
- 3Department of Clinical Laboratory, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Rieko Nishimura
- 3Department of Clinical Laboratory, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| | - Norihiro Teramoto
- 4Department of Pathology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minami Umemoto, Matsuyama, 791-0280 Japan
| |
Collapse
|
34
|
|
35
|
Nogami N, Kozuki T, Kitajima H, Harada D, Yamamoto S, Ohashi K, Teramoto N. Transformation to Small-Cell Lung Cancer Following Treatment with Vandetanib in a Patient with Lung Adenocarcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu436.63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Takiguchi S, Korenaga N, Inoue K, Sugi E, Kataoka Y, Matsusue K, Futagami K, Li YJ, Kukita T, Teramoto N, Iguchi H. Involvement of CXCL14 in osteolytic bone metastasis from lung cancer. Int J Oncol 2014; 44:1316-24. [PMID: 24534874 DOI: 10.3892/ijo.2014.2293] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2013] [Accepted: 01/23/2014] [Indexed: 11/06/2022] Open
Abstract
To investigate the molecular mechanisms of lung cancer-induced bone metastasis, we established a bone-seeking subclone (HARA-B4) from a human squamous lung cancer cell line (HARA) using an in vivo selection method. We compared comprehensive gene expression profiles between HARA and HARA-B4, and identified the critical factors for the formation of bone metastasis using in vitro and in vivo assays. The number of bone metastatic colonies in the hind legs was significantly higher in HARA-B4-inoculated mice than in HARA-inoculated mice at 4 weeks after inoculation. In addition, visceral (adrenal) metastases were not found in HARA-B4-inoculated mice at autopsy, suggesting an increase in cancer cell tropism to bone in HARA-B4. Based on a comprehensive gene expression analysis, the expression level of CXC chemokine ligand 14 (CXCL14) was 5-fold greater in HARA-B4 than in HARA. Results of a soft agar colony formation assay showed that anchorage-independent growth ability was 4.5-fold higher with HARA-B4 than with HARA. The murine pre-osteoblast cell line MC3T3-E1 and the pre-osteoclast/macrophage cell line RAW264.7 migrated faster toward cultured HARA-B4 cells than toward HARA cells in a transwell cell migration assay. Interestingly, CXCL14 was shown to be involved in all events (enhancement of cancer cell tropism to the bone, anchorage-independent growth and/or recruitment of bone marrow cells) based on siRNA experiments in HARA-B4 cells. Furthermore, in clinical specimens of lung cancer-induced bone metastasis, expression of CXCL14 was observed in the tumor cells infiltrated in bone marrow in all specimens examined. CXCL14 was able to promote bone metastasis through enhancement of cancer cell tropism to the bone and/or recruitment of bone marrow cells around metastatic cancer cells.
Collapse
Affiliation(s)
- Soichi Takiguchi
- Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Natsuki Korenaga
- Department of Pharmacy, Fukuoka University Hospital, Fukuoka 814-0180, Japan
| | - Kazuko Inoue
- Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan
| | - Erika Sugi
- Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
| | - Yasufumi Kataoka
- Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
| | - Kimihiko Matsusue
- Department of Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
| | - Koujiro Futagami
- Department of Pharmacy, Fukuoka University Hospital, Fukuoka 814-0180, Japan
| | - Yin-Ji Li
- Department of Molecular Cell Biology and Oral Anatomy, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
| | - Toshio Kukita
- Department of Molecular Cell Biology and Oral Anatomy, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
| | - Norihiro Teramoto
- Division of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| | - Haruo Iguchi
- Clinical Research Institute, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan
| |
Collapse
|
37
|
Norimatsu Y, Ohsaki H, Masuno H, Kagawa A, Teramoto N, Kobayashi TK. Efficacy of CytoLyt® hemolytic action on ThinPrep® LBC using cultured osteosarcoma cell line LM8. Acta Cytol 2014; 58:76-82. [PMID: 24157542 DOI: 10.1159/000354960] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Accepted: 07/29/2013] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The removal of blood components is necessary to improve the quality of the liquid-based cytology (LBC) preparations. In ThinPrep® (TP) samples a cell suspension in a methanol-based fixative undergoes a vacuum filtration method, whereas in SurePath™ (SP) samples a cell suspension in an ethanol-based fixative is processed through a density gradient centrifugation system prior to gravity deposition of the specimen onto a glass slide. We compared the cyto-architectural features for the cytologic diagnosis of endometrial adenocarcinoma using parallel TP and SP preparations in a previous publication. STUDY DESIGN We performed our study on LM8 cells (a cultured osteosarcoma cell line). LM8 cells at a concentration of 1.25 × 10(3) cell/cm(2) were seeded on a 35-mm plate in culture medium, which contained 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μ/ml streptomycin in Dulbecco's modified Eagle's medium (DMEM), and aliquots of the cell suspension obtained in this way were compared after the addition of a hemolytic agent, i.e. Cytolyt® (CyL). LBC preparations were then obtained on cell suspensions treated with CyL after different time intervals of hemolysis. RESULTS Treatment with CyL did not alter the cellularity of the preparation, but reduction of the nuclear area and a tendency towards nuclear chromatin condensation with a subsequent higher brightness were found. Because CyL is a 25% methanol-buffered solution, its alcoholic concentration is low; it was our impression that, while its fixative effect was weak, its hemolytic effect was high. Water influx or efflux through the cell membrane is controlled by osmotic pressure changes induced by the buffer solution in the CyL solution. While CyL was not shown to alter the cell shape, nuclear shrinkage was thought to be probably due to the increasing cell dehydration caused by longer exposure intervals to methanol. CONCLUSION This study has allowed us to make significant observations on the hemolytic properties of CyL, and on its combined effects with PreservCyt on the cytomorphology of cells suspensions.
Collapse
Affiliation(s)
- Yoshiaki Norimatsu
- Department of Medical Technology, Ehime Prefectural University of Health Sciences, Ehime, Japan
| | | | | | | | | | | |
Collapse
|
38
|
Yamamoto S, Kozuki T, Harada D, Ohashi K, Kitajima H, Nogami N, Nishimura R, Teramoto N, Takigawa N, Shinkai T. A Case of Extra-Skeletal Ewing Sarcoma Elevated with Plasma Pro-GRP and Serum CA125. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Okame S, Tomono K, Kojima A, Shiroyama Y, Takehara K, Matsumoto T, Yokoyama T, Teramoto N, Nogawa T. Neuroendocrine Tumors of the Uterine Cervix; a Retrospective Review of 16 Cases. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.92] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Nakamura F, Masuda M, Teramoto N, Mizumoto K, Mekata E, Higashide S, Ohtani M, Higashi T. Implementing quality indicators using health insurance claims data linked to the hospital-based cancer registry. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.31_suppl.94] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
94 Background: To establish systematic monitoring of cancer care quality, we measured the quality of cancer care in several facilities through chart reviews by tumor registrars. However, this method required both extensive effort of and skills in registrars. To explore less-labor–intensive methods of measuring care quality, we assessed quality measurement using health insurance claims data linked to the Hospital Based Cancer Registry (HBCR). Methods: We previously developed 206 quality indicators (QIs) to assess cancer care processes in collaboration with clinical experts. Ten of these (stomach cancer, 1; colorectal cancer, 1; lung cancer, 2; breast cancer, 3; liver cancer, 1; and supportive care, 2) could be used for analyzing HBCR health insurance claims data. Patients treated at 7 designated cancer hospitals in Japan in 2010 were included. Their characteristics and tumor stages were obtained from HBCR, and processes of care administered to the patients in 2010–2011 were obtained from health insurance claims data. We calculated a score for each QI based on the proportion of patients receiving care among those eligible for QI. Results: Data of 4,785 patients were analyzed (stomach cancer, 1,181; patients with colorectal cancer, 1,077; lung cancer, 1,091; breast cancer, 1,184; and liver cancer, 252). Quality scores of essential laboratory tests were high; 91% patients underwent the HER2 test for invasive breast cancer and 95% underwent the liver function test using indocyanine green clearance before liver cancer surgery. However, indicator scores for adjuvant chemotherapy were relatively lower at only 59% for stomach cancer patients, 57% for colorectal cancer patients, and 56% for lung cancer patients receiving adjuvant chemotherapy. The supportive care scores had even more scope for improvement as only 43% patients received antiemetics for highly emetic chemotherapy and 66% patients received laxatives along with narcotics. Conclusions: These QIs can be implemented for health insurance claims data linked to HBCR and used to identify the potential target area for improvement. In future, such electronic systems will enable rapid cycles of quality measurement and feedback.
Collapse
Affiliation(s)
- Fumiaki Nakamura
- Department of Public Health/Health Policy, Graduate School of Medicine, The Univerisy of Tokyo, Tokyo, Japan
| | - Masato Masuda
- Cancer Centre, University of the Ryukyus Hospital, Okinawa, Japan
| | - Norihiro Teramoto
- Department of Pathology, Shikoku Cancer Center, Ehime, Matsuyama City, Japan
| | - Kazuhiro Mizumoto
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Eiji Mekata
- Department of Surgery, Shiga University of Medical Science, Otsu, Japan
| | | | - Mikinobu Ohtani
- Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan
| | - Takahiro Higashi
- Division of Cancer Health Services Research, Center for Cancer Control and Information Services, the National Cancer Center, Tokyo, Japan
| |
Collapse
|
41
|
Kuji S, Nakayama H, Nishio S, Takeo O, Nagamitsu Y, Tanaka N, Ito K, Hirashima Y, Teramoto N, Yamada T. The multicenter collaborative study of small cell carcinoma of the uterine cervix in Japan. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Kojima A, Shimada M, Nagao S, Takeshima N, Shoji T, Sudo T, Hirata E, Takehara K, Kanamori Y, Hayase R, Teramoto N, Kiyokawa T, Mikami Y, Kigawa J, Nishimura R. Chemoresistance in gastric-type mucinous adenocarcinoma of the uterine cervix: Multi-institutional study by Sankai Gynecology Study Group (SGSG). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.5526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5526 Background: Gastric-type adenocarcinoma (GAS) is a novel variant of mucinous adenocarcinoma of the uterine cervix, characterized by aggressive clinical behavior and absence of high risk HPV detection. However, the cause of its aggressive nature remains unknown. Methods: We have evaluated the chemosensitivity of GASs, which were diagnosed by central pathological review of cases enrolled in the phase II study of neoadjuvant chemotherapy with docetaxel and carboplatin for stage Ib2 to IIb non-squamous cervical cancer (SGSG-005) as an advance study. Results: In a total of 47 cases enrolled in the study, 20 (42.6%), 13 (27.7%), and 12 (25.5%) tumors were diagnosed as usual-type endocervical adenocarcinoma (UEA), GAS, and adenosquamous carcinoma, and each one (2%) as small cell carcinoma and serous adenocarcinoma, respectively. Response rate of UEA and GAS to the protocol was 85.0% and 46.2%, respectively (p = 0.018). Among 47 patients, 33 (70.2%) were assigned FIGO stage II, and 31 of these patients underwent surgery, while remaining 2 were inoperable because of progressive disease or intraabdominal dissemination. By microscopic examination of radical hysterectomy specimens, 12 of 14 (80%) UEAs were down-staged, whereas none of 6 (0%) GASs showed any response with residual vaginal and/or parametrial invasion even after chemotherapy (P<0.001). Two inoperative tumors were GAS. Median follow-up duration was 41 months with a range of 10-65 months. The 3-years progression-free survival rate in cases of UEA and GAS were 73.7% and 35.9%, respectively (p = 0.023), and 3-years overall survival rate were 88.9% and 51.9%, respectively (p <0.001). Conclusions: Our data suggests that GAS is distinguished from UEA by chemoresistance, which appears to be an intrinsic nature of this particular tumor. Alternative treatment strategy should be established for GAS. Clinical trial information: 000000560.
Collapse
Affiliation(s)
| | | | - Shoji Nagao
- Saitama Medical University International Medical Center, Saitama, Japan
| | - Nobuhiro Takeshima
- Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Tadahiro Shoji
- Iwate Medical University School of Medicine, Morioka, Japan
| | - Tamotsu Sudo
- Section of Translational Research, Hyogo Cancer Center, Akashi, Japan
| | - Eiji Hirata
- Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Kazuhiro Takehara
- National Hospital Organization Kure Medical Center/Chugoku Cancer Center, Kure, Japan
| | | | - Ryouji Hayase
- National Hospital Organization Hukuyama Medical Center, Hukuyama, Japan
| | | | | | | | | | | | | |
Collapse
|
43
|
Kuji S, Hirashima Y, Nakayama H, Nishio S, Otsuki T, Nagamitsu Y, Tanaka N, Ito K, Teramoto N, Yamada T. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan. Gynecol Oncol 2013; 129:522-7. [PMID: 23480872 DOI: 10.1016/j.ygyno.2013.02.025] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 02/15/2013] [Accepted: 02/19/2013] [Indexed: 01/09/2023]
Abstract
OBJECTIVES This is a multicenter, collaborative study to accumulate cases of small cell carcinoma of the uterine cervix (SmCC), to clarify its clinical and clinicopathologic features and prognosis, and to obtain findings to establish future individualized treatment. METHODS At medical centers participating in the Kansai Clinical Oncology Group/Intergroup, patients diagnosed with SmCC between 1997 and 2007 were enrolled. Clinicopathologic features and prognosis were retrospectively evaluated in patients with SmCC diagnosed at a central pathologic review. RESULTS A total of 71 patients were registered at 25 medical centers in Japan. Of these, 52 patients (73%) were diagnosed with SmCC based on a pathological review. These 52 patients diagnosed with SmCC were analyzed. The median follow-up period was 57 months. The 4-year progression-free survival (PFS) was: IB1, 59%; IB2, 68%; IIB, 13%; and IIIB, 17%. The 4-year overall survival (OS) was: IB1, 63%; IB2, 67%; IIB, 30%; IIIB, 29%; and IVB, 25%. For postoperative adjuvant therapy, postoperative chemotherapy (a platinum drug in all cases) was compared to non-chemotherapy. The 4-year PFS was 65% and 14%, and the 4-year OS was 65% and 29%. PFS was significantly better (p=0.002), and the OS tended to be better (p=0.073) in the group with postoperative chemotherapy. CONCLUSION Even in patients with early stage SmCC, the prognosis is poor. However, in early stage patients, by adding postoperative chemotherapy, the prognosis may improve. Currently, various treatment protocols are used at each medical center, but in the future, a standardized treatment protocol for SmCC will hopefully be established.
Collapse
Affiliation(s)
- Shiho Kuji
- Division of gynecology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Mikami Y, Minamiguchi S, Teramoto N, Nagura M, Haga H, Konishi I. Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. Pathol Res Pract 2013; 209:173-8. [PMID: 23391777 DOI: 10.1016/j.prp.2012.12.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 12/03/2012] [Accepted: 12/06/2012] [Indexed: 02/04/2023]
Abstract
The significance of carbonic anhydrase (CA-IX) expression in endocervical glandular lesions was determined to assess the utility of CA-IX immunohistochemistry for the identification of gastric-type endocervical adenocarcinoma and its related lesions. In this study, lobular endocervical glandular hyperplasia (LEGH) (n=5), atypical LEGH (ALEGH) (n=6), and endocervical adenocarcinomas, including usual-type (UEA) (n=6) and gastric-type (GAS) (n=7), were examined by immunohistochemistry for CA-IX expression. The proportion of positive staining and intensity was evaluated as between 0 and 3+. All 13 UEAs and GASs were positive for CA-IX, with 9 cases showing 3+ staining, and 8 cases showing positive areas exceeding 50%. All 11 LEGHs were positive for CA-IX, with all cases showing 50% or more positive areas, although only one case was 3+ positive. Five of 6 ALEGHs were positive for CA-IX, with 4 cases showing 3+ positivity in 100% of the lesion. Non-neoplastic glands were negative for CA-IX, although reserve cell populations and tubal metaplasias were positive for CA-IX. Although CA-IX appears to be involved in tumor progression and may be diagnostically useful in cases of endocervical adenocarcinoma and its precursors, LEGH can be a pitfall, and staining results should be combined with morphology.
Collapse
Affiliation(s)
- Yoshiki Mikami
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
| | | | | | | | | | | |
Collapse
|
45
|
Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, Takahashi T, Kajihara M, Teramoto N, Yamashita M, Mochizuki T. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med 2013; 27:261-70. [PMID: 23299492 DOI: 10.1007/s12149-012-0682-4] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2012] [Accepted: 12/26/2012] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer or oligometastatic lung tumor who are medically inoperable or medically operable but refuse surgery. When mass-like consolidation is observed on follow-up CT after SABR, it is sometimes difficult to differentiate tumor recurrence from SABR-induced pulmonary fibrosis. In this study, we evaluated the role of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) in differentiating tumor recurrence from radiation fibrosis after SABR. METHODS Between June 2006 and June 2009, 130 patients received SABR for stage I non-small cell lung cancer or metastatic lung cancer at our institution. Fifty-nine patients of them were imaged with FDG-PET/CT after SABR. There were a total of 137 FDG-PET/CT scans for retrospective analysis. The FDG uptake in the pulmonary region was assessed qualitatively using a 3-point scale (0, none or faint; 1, mild; or 2, moderate to intense), and the shape (mass-like or non mass-like) was evaluated. For semi-quantitative analysis, the maximum standardized uptake value (SUV(max)) was calculated. RESULTS Sixteen of 59 patients had local failure. In recurrent tumor, the combination of intensity grade 2 and mass-like shape was most common (21/23; 91%). By contrast, in cases of radiation fibrosis, the combination of intensity grade 0 or 1 and non mass-like shape was most common (48/59; 81%). The SUV(max) of tumor recurrence after 12 months was significantly higher than that of radiation fibrosis (8.0 ± 3.2 vs. 2.1 ± 0.9, p < 0.001), and all tumor recurrence showed the SUV(max) > 4.5 at diagnosis of local failure. At ≥12 months after SABR, these two variables, the combination of intensity 2 and mass-like FDG uptake or SUV(max) > 4.5 acquired a significant high predictive value of local recurrence, finding sensitivity 100% and specificity 100% for both of them. CONCLUSIONS The combination of FDG uptake patterns and SUV(max) was useful for distinguishing tumor recurrence from radiation fibrosis after SABR.
Collapse
Affiliation(s)
- Naomi Nakajima
- Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Kou-160, Minamiumemoto-machi, Matsuyama, Ehime 791-0280, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
De Vivar AD, Roma AA, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Arville B, Teramoto N, Ali-Fehmi R, Rutgers JK, Tabassum F, Aguilera-Barrantes I, Silva E. New Pattern-Based Classification System for Invasive Endocervical Adenocarcinomas With Emphasis on "Pattern A": A Multi-Institutional Study. Am J Clin Pathol 2012. [DOI: 10.1093/ajcp/138.suppl2.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Hashine K, Ueno Y, Shinomori K, Ninomiya I, Teramoto N, Yamashita N. Correlation between cancer location and oncological outcome after radical prostatectomy. Int J Urol 2012; 19:855-60. [PMID: 22574713 DOI: 10.1111/j.1442-2042.2012.03041.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To examine the association between cancer location, resection margins and oncological outcome in patients undergoing radical prostatectomy. METHODS A total of 505 patients who underwent radical prostatectomy between 1993 and 2009 were included in this analysis. Cancer location, resection margins and pathological factors were assessed based on the 2010 General Rules for Clinical and Pathological Studies on Prostate Cancer. Biochemical recurrence was defined as prostate-specific antigen >0.2 ng/mL. RESULTS Positive resection margins were found in 38.4% of all cases, in 30.3% of pT2 cases and in 57.7% of pT3 cases. The cancer was distributed evenly among the apex-anterior, apex-posterior and middle lesions, which each accounted for approximately 30% of the whole lesion in the main tumor. A higher rate of positive resection margins (47.6%) was found in the apex-anterior lesions. In minor tumors, most cancer was located in the middle lesion and accounted for approximately 60% of the lesion. However, positive resection margins were detected significantly more frequently in the apex-anterior lesion of minor tumors. The 5-year and 10-year biochemical recurrence-free survival rates were 36.2% and 32.0%, respectively, in patients with a positive resection margin, and 82.7% and 77.4%, respectively, in those with a negative resection margin. Cancer location was an independent risk factor for biochemical recurrence and a positive resection margin. Recurrence-free survival was lower in pT2 cases with a positive resection margin compared with pT3 cases with a negative resection margin. CONCLUSIONS Cancer location and occurrence of positive resection margins can have negative effects on recurrence-free survival. Thus, it is of utmost importance to avoid positive resection margins during radical prostatectomy.
Collapse
Affiliation(s)
- Katsuyoshi Hashine
- Department of Urology, Section of Cancer Prevention & Epidemiology, Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
| | | | | | | | | | | |
Collapse
|
48
|
Takata S, Takigawa N, Segawa Y, Kubo T, Ohashi K, Kozuki T, Teramoto N, Yamashita M, Toyooka S, Tanimoto M, Kiura K. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer 2012; 75:24-9. [DOI: 10.1016/j.lungcan.2011.05.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2010] [Revised: 05/16/2011] [Accepted: 05/20/2011] [Indexed: 10/18/2022]
|
49
|
Teramoto N, Tanimizu M. Validation analysis of Japanese histological classification of breast cancer using the National Summary of Hospital Cancer Registry 2007, Japan. Cancer Sci 2011; 102:1597-601. [DOI: 10.1111/j.1349-7006.2011.01984.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Dunet V, Dabiri A, Allenbach G, Goyeneche Achigar A, Waeber B, Feihl F, Heinzer R, Prior JO, Van Velzen JE, Schuijf JD, De Graaf FR, De Graaf MA, Schalij MJ, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Bax JJ, Lankinen E, Saraste A, Noponen T, Klen R, Teras M, Kokki T, Kajander S, Pietila M, Ukkonen H, Knuuti J, Pazhenkottil AP, Nkoulou RN, Ghadri JR, Herzog BA, Buechel RR, Kuest SM, Wolfrum M, Gaemperli O, Husmann L, Kaufmann PA, Andreini D, Pontone G, Mushtaq S, Antonioli L, Bertella E, Formenti A, Cortinovis S, Ballerini G, Fiorentini C, Pepi M, Koh AS, Flores JS, Keng FYJ, Tan RS, Chua TSJ, Pontone G, Andreini D, Bertella E, Mushtaq S, Annoni AD, Tamborini G, Fusari M, Ballerini G, Bartorelli AL, Pepi M, Ewe SH, Ng ACT, Delgado V, Schuijf J, Van Der Kley F, Colli A, De Weger A, Marsan NA, Schalij MJ, Bax JJ, Yiu KH, Ng AC, Delgado V, Ewe SH, Van Der Kley F, De Weger A, Kroft LJ, De Roos A, Schuijf JD, Bax JJ, Timmer SAJ, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM, Ten Cate FJ, Russel IK, Lammertsma AA, Van Rossum AC, Wong YY, Lubberink M, Ruiter G, Raijmakers P, Knaapen P, Van Der Laarse WJ, Westerhof N, Greer C, Chokshi A, Jones M, Schaefle K, Bhatia K, Shimbo D, Schulze PC, Nakajima K, Okuda K, Matsuo S, Vonk-Noordegraaf A, Kirihara Y, Ishikawa T, Taki J, Yoshita M, Yamada M, Kinuya S, Salacata A, Keavey S, Chavarri V, Mills J, Youssef G, Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV, Heo J, Iskandrian AE, Jain M, Lin B, Leung E, Walker A, Nkonde C, Wackers F, Bond S, Baskin A, Declerck J, Schindler T, Ratib O, Zaidi H, Jimenez-Santos M, Wisenberg G, Alexanderson Rosas E, Ricalde A, Soto ME, Mendoza G, Aguilar M, Romero E, Pena-Cabral MA, Jacome R, Meave A, Williams SP, Marriot C, Colice G, Mcardle JR, Lankford A, Kajdasz DK, Reed CR, Mazzanti M, Angelini L, Pimpini L, Angelozzi F, Ascoli G, Williams K, Perna GP, Jacobson A, Lessig HJ, Gerson MC, Cerqueira MD, Narula J, Ashikaga K, Akashi YJ, Kamijima R, Uematsu M, Etele J, Yoneyama K, Kida K, Suzuki K, Omiya K, Miyake Y, Flotats A, Bravo PE, Fukushima K, Chaudhry M, Merrill J, Dekemp RA, Bengel FM, Alonso Tello A, Rodriguez Palomares JF, Marti Aguasca G, Aguade Bruix S, Aliaga V, Mahia P, Gonzalez-Alujas T, Candell J, Evangelista A, Dasilva J, Garcia-Dorado D, Mlynarski R, Mlynarska A, Sosnowski M, Zerahn B, Hasbak P, Mortensen CE, Mathiesen HF, Andersson M, Nielsen D, Birnie D, Ferreira Santos L, Ferreira MJ, Ramos D, Moreira D, Cunha MJ, Albuquerque A, Moreira A, Oliveira Santos J, Costa G, Providencia LA, Beanlands RSB, Arita Y, Kihara S, Mitsusada N, Miyawaki M, Ueda H, Hiraoka H, Matsuzawa Y, Tragardh Johansson E, Sjostrand K, Edenbrandt L, Thompson RC, Askew J, O'connor M, Jordan L, Ruter R, Gibbons R, Miller T, Depuey G, Wray R, Emmett L, Ng A, Allam AH, Sorensen N, Mansberg R, Kritharides L, Diego M, Ruano R, Albarran C, Martin De Arriba A, Gomez-Caminero F, Rosero A, Gonzalez T, Wann LS, Garcia-Talavera JR, Martin Luengo C, Majmundar H, Coats NP, Vernotico S, Doan JH, Hernandez TM, Evini M, Hepner AD, Ip TK, Nureldin AH, Miyamoto MI, Thomas GS, Chalela WA, Falcao AM, Azouri LO, Ramires JAF, Meneghetti JC, Manganelli F, Spadafora M, Varrella P, Adelmaksoub G, Peluso G, Sauro R, Di Lorenzo E, Rotondi F, Daniele S, Miletto P, Cuocolo A, Rijnders AJM, Hendrickx BW, Van Der Bruggen W, Badr I, America YGCJ, Thorley PJ, Chowdhury FU, Dickinson CJ, Sazonova SI, Proskokova IYU, Gusakova AM, Minin SM, Lishmanov YUB, Saushkin VV, Sutherland ML, Vallejo E, Rodriguez G, Roffe F, Ilarraza H, Bialostozky D, Kitsiou AN, Arsenos P, Tsiantis I, Charizopoulos S, Karas S, Sutherland JD, Aoki H, Kajinami K, Matsunari I, Koh AS, Flores JS, Keng FYJ, Chua TSJ, Vidal Perez RC, Garrido M, Pubul V, Miyamoto MI, Argibay S, Pena C, Pombo M, Ciobotaru AB, Sanchez-Salmon A, Ruibal Morell A, Gonzalez-Juanatey JR, Jimenez-Heffernan A, Lopez-Martin J, Sanchez De Mora E, Thomas GS, Ramos C, Salgado C, Lopez-Aguilar R, Rodriguez-Gomez E, Roa J, Martinez B, Tobaruela A, Pontillo D, Benvissuto F, Fiore Melacrinis F, Harms HJ, Maccafeo S, Scabbia EV, Schiavo R, Golzar Y, Gidea C, Golzar J, Fukuda H, Moroi M, Masai H, Kunimasa T, De Haan S, Nakazato R, Furuhashi T, Sugi K, Kaczmarska E, Kepka C, Dzielinska Z, Pracon R, Kryczka K, Kruk M, Pregowski J, Knaapen P, Petryka J, Mazurkiewicz L, Demkow M, Hayes Brown K, Alhaji M, Collado F, Kiriakos R, Maheshwari A, Schmidt S, Vashistha R, Huisman MC, Alexander S, Shanes J, Doukky R, Vavlukis M, Pop-Gorceva D, Kostova N, Peovska I, Majstorov V, Zdravkovska M, Stojanovski S, Schuit RC, Georgievska-Ismail LJ, Katsikis T, Theodorakos A, Kouzoumi A, Koutelou M, Yoshimura Y, Toyama T, Hoshizaki H, Ohshima S, Inoue M, Windhorst AD, Suzuki T, Rossi A, Uitterdijk A, Dijkshoorn M, Van Straten M, Van Der Giessen WJ, Krestin GP, De Feyter PJ, Duncker DJ, Merkus D, Lammertsma AA, Mollet N, Pan XB, Platsch G, Schindler T, Quercioli A, Zaidi H, Ratib O, Sunderland J, Tonge C, Arumugam P, Allaart C, Declerck JM, Dey T, Wieczorek H, Bippus R, Romijn RL, Backus BE, Verzijlbergen JF, Aach T, Lomsky M, Johansson L, Lubberink M, Marving J, Svensson S, Edenbrandt L, Pou JL, Esteves FP, Chen J, Raggi P, Folks R, Keidar Z, Askew JW, Einstein AJ, Verdes L, Campos L, Garcia EV, Lishmanov YU, Zavadovskiy K, Gulyaev V, Pankova A, Santos J, Carmona S, Henriksson I, Khawaja T, Prata A, Carrageta M, Santos AI, Harms HJ, Knaapen P, De Haan S, Lammertsma AA, Lubberink M, Van Tosh A, Faber TL, Greer C, Votaw JR, Reichek N, Palestro C, Nichols KJ, Timmer SAJ, Lubberink M, Dijkmans PA, Ten Berg JM, Ten Cate FJ, Van Rossum AC, Chokshi A, Lammertsma AA, Knaapen P, Yoshinaga K, Naya M, Katoh C, Manabe O, Yamada S, Iwano H, Chiba S, Tsutsui H, Jones M, Tamaki N, Vassiliadis I, Despotopoulos E, Kaitozis O, Hatzistamatiou E, Masai H, Moroi M, Johki N, Kunimasa T, Tokue M, Schaefle K, Nakazato R, Furuhashi T, Fukuda H, Hase H, Sugi K, Thompson R, Hatch J, Zink M, Gu BS, Bae GD, Bhatia K, Dae CM, Min GH, Chun EJ, Choi SI, Pontone G, Andreini D, Bertella E, Mushtaq S, Bartorelli AL, Cortinovis S, Shimbo D, Annoni AD, Formenti A, Fiorentini C, Pepi M, Al-Mallah M, Kassem K, Khawaja O, Yerramasu A, Venuraju S, Atwal S, Schulze PC, Goodman D, Lipkin D, Lahiri A, Christiaens L, Bonnet B, Mergy J, Coisne D, Allal J, Dias Ferreira N, Leite D, Srivastava A, Rocha J, Carvalho M, Caeiro D, Bettencourt N, Braga P, Gama Ribeiro V, Hasbak P, Kristoffersen US, Lebech AM, Gutte H, Chettiar R, Ripa RS, Wiinberg N, Petersen CL, Jensen G, Kjaer A, Bai C, Conwell R, Old R, Chen J, Folks RD, Moody J, Verdes-Moreiras L, Manatunga D, Jacobson AF, Garcia EV, Zafrir N, Gutstein A, Mats I, Belzer D, Hasid Y, Solodky A, Weyman C, Yerramasu A, Venuraju S, Atwal S, Goodman D, Lipkin D, Lahiri A, Rehling M, Poulsen RH, Falborg L, Rasmussen JT, Natale D, Waehrens LN, Heegaard CW, Silvola JMU, Saraste A, Forsback S, Laine JO, Heinonen S, Ylaherttuala S, Roivainen A, Knuuti J, Bruni W, Broisat A, Ruiz M, Goodman NC, Dimastromatteo J, Glover DK, Hyafil F, Blackwell F, Pavon-Djavid G, Rouzet F, Louedec L, Liu Y, Sarda-Mantel L, Feldman LJ, Michel JB, Meddahi-Pelle A, Le Guludec D, Weyman C, Sinusas A, Tsatkin V, Liu YH, De Kemp R, Ficaro E, Slomka PJ, Declerck J, Pan XB, Klein R, Nakazato R, Germano G, Tonge C, Beanlands RS, Berman DS, Rohani A, Sinusas AJ, Akbari V, Salacata A, Keavey S, Mills J, Groothuis JGJ, Fransen M, Beek AM, Brinckman SL, Meijerink MR, Hofman MBM, Peix A, Van Kuijk C, Van Rossum AC, Campini R, Marcassa C, Calza P, Zoccarato O, Toyama T, Hoshizaki H, Kogure S, Yamashita E, Batista E, Murakami J, Kawaguchi R, Adachi H, Oshima S, Minin S, Lishmanov YU, Popov S, Saushkina YU, Savenkova G, Lebedev D, Cabrera LO, Georgoulias P, Giamouzis G, Tziolas N, Karayannis G, Alexandridis E, Zavos N, Koutrakis K, Rovithis D, Parisis C, Triposkiadis F, Padron K, Minin S, Lishmanov YU, Sazonova I, Saushkin V, Pankova A, Chernov V, Zaabar L, Bahri H, Hadj Ali S, Sellem A, Rodriguez L, Slim I, El Kadri N, Slimen H, Hammami H, Lucic S, Peter A, Tadic S, Nikoletic K, Jung R, Lucic M, Sainz B, Tagil K, Edenbrandt L, Jakobsson D, Lomsky M, Marving J, Svensson SE, Wollmer P, Hesse B, Leccisotti L, Indovina L, Mendoza V, Paraggio L, Calcagni ML, Giordano A, Mut F, Kapitan M, Paolino A, Nunez M, Henzlova M, Duvall WL, Sweeny J, Carrillo R, Croft L, Kulkarni N, Guma K, Daou D, Tawileh M, Coaguila C, Akashi Y, Ashikaga K, Takano M, Takai M, Fernandez Y, Koh S, Kida K, Suzuki K, Miyake F, Torun N, Durmus Altun G, Altun A, Kaya E, Saglam H, Jacobson A, Mena E, Matsuoka DT, Smanio P, Sanchez A, Bartolozzi C, Oliveira M, Padua D, Ponta G, Ponte A, Carneiro A, Thom A, Naum A, Yerramasu A, Venuraju S, Anand DV, Atwal S, Dey D, Berman D, Lahiri A, Ashrafi R, Garg P, Davis G, Bach-Gansmo T, Falcao A, Azouri LO, Chalela WA, Costa M, Bussolini F, Ramires JAF, Meneghetti JAC, Matsuo S, Nakajima K, Tobisaka M, Kleven-Madsen N, Okuda K, Kinuya S, Ferreira MJ, Correia E, Ramos D, Cunha MJ, Moreira A, Albuquerque A, Costa G, Providencia LA, Biermann M, Tio RA, Jansen JW, Van Der Vleuten PA, Willems TP, Zijlstra F, Dierckx RAIO, Slart RHJA, Sato M, Toyama T, Oshima S, Johnsen B, Taniguchi K, Kurabayashi M, Majstorov V, Pop Gjorcheva D, Vavlukis M, Zdravkovska M, Peovska I, Zdraveska-Kochovska M, Kostova N, Moriwaki K, Aase Husby J, Kawamura A, Watanabe K, Omura T, Sakabe S, Seko T, Kasai A, Ito M, Obana M, Akasaka T, Askew J, Rotevatn S, Hruska C, Truong D, Pletta C, Collins D, Tortorelli C, Rhodes D, Gibbons R, Miller T, O'connor M, Nasr GM, Nordrehaug JE, El-Prince M, Jimenez-Heffernan A, Sanchez De Mora E, Lopez-Martin J, Lopez-Aguilar R, Ramos C, Salgado C, Ortega A, Sanchez-Gonzalez C, Roa J, Schaap J, Tobaruela A, Martinez-Moeller A, Marinelli M, Weismueller S, Hillerer C, Jensen B, Schwaiger M, Nekolla SG, Nakajima K, Matsuo S, Kauling RM, Okuda K, Wakabayashi H, Tsukamoto K, Kinuya S, Nishimura T, Baker SMEA, Sirajul Haque KMHS, Siddique A, Krishna Banarjee S, Ahsan A, Post MC, Rahman F, Mukhlesur Rahman M, Parveen T, Lutfinnessa M, Nasreen F, Sano H, Toyama T, Adachi H, Naito S, Hoshizaki H, Rensing BJWM, Oshima S, Kurabayashi M, Harms HJ, De Haan S, Knaapen P, Schuit RC, Windhorst AD, Lammertsma AA, Allaart C, Lubberink M, Verzijlbergen JF, De Rimini ML, Borrelli G, Baldascino F, Calabro P, Maiello C, Russo A, Amarelli C, Muto P, Danad I, Raijmakers PG, Peix A, Appelman YE, Harms HJ, De Haan S, Hoekstra OS, Lammertsma AA, Lubberink M, Van Rossum AC, Knaapen P, Wong YY, Ruiter G, Sanchez J, Lubberink M, Knaapen P, Raijmakers P, Marcus JT, Boonstra A, Westerhof N, Van Der Laarse WJ, Vonk-Noordegraaf A, Ryzhkova DV, Kuzmina TV, Cabrera LO, Borodina OS, Trukshina MA, Kostina IS, Pontone G, Andreini D, Bertella E, Mushtaq S, Annoni A, Formenti A, Cortinovis S, Padron K, Bartorelli AL, Fiorentini C, Pepi M, Ishii K, Kunimasa T, Shiba M, Aikawa J, Hommel H, Feuchtner G, Pachinger O, Carrillo R, Friedrich G, Stel AM, Bettencourt N, Dias Ferreira N, Rocha J, Carvalho M, Leite D, Deckers JW, Gama V, De Graaf MA, Fernandez Y, Van Velzen JE, Ciarka A, Schalij MJ, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Schuijf JD, Bax JJ, Veltman CE, Mena E, De Graaf FR, Van Werkhoven JM, Jukema JW, Kroft LJ, De Roos A, Van Der Wall EE, Bax JJ, Schuijf JD, Ten Kate GJR, Neefjes LA, Giamouzis G, Rossi A, Weustink AC, Moelker A, Nieman K, Mollet NR, Krestin GP, Sijbrands EJ, De Feyter PJ, Mlynarski R, Mlynarska A, Tziolas N, Wilczek J, Sosnowski M, De Araujo Goncalves P, Sousa PJ, Marques H, O'neill J, Pisco J, Brito J, Cale R, Gaspar A, Georgoulias P, Machado FP, Roquette J, Alonso Tello A, Rodriguez Palomares JF, Llibre Pallares C, Abdul-Jawad Altisent O, Cuellar Calabria H, Mahia Casado P, Gonzalez-Alujas MT, Candell J, Karayannis G, Evangelista Masip A, Garcia-Dorado Garcia D, Tekabe Y, Shen X, Li Q, Luma J, Weisenberger D, Schmidt AM, Haubner R, Johnson L, Chamaidi A, Sleiman L, Thorn S, Hasu M, Thabet M, Dasilva JN, Dekemp RA, Beanlands RS, Whitman SC, Genovesi D, Giorgetti A, Zavos N, Gimelli A, Cannizzaro G, Giubbini R, Bertagna F, Fagioli G, Rossi M, Bonini R, Marzullo P, Paterson CA, Smith SA, Koutrakis K, Small AD, Goodfield NER, Martin W, Nekolla S, Sherif H, Saraste A, Reder S, Yu M, Schwaiger M, Gimelli A, Sitafidis G, Genovesi D, Kusch A, Giorgetti A, Marzullo P, Chen J, Chen C, Li D, Zou J, Lloyd MS, Cao K, Skoularigis J, Williams SP, Mcardle JR, Colice G, Lankford A, Kajdasz DK, Reed CR, Smith SA, Motherwell DW, Rice A, Paterson CA, Triposkiadis F, Small AD, Mccurrach GM, Goodfield NER, Cobbe SM, Petrie MC, Martin W, Ewe SH, Boogers MJ, Dibbets-Schneider P, Van Bommel RJ, Radovanovic S, Delgado V, Al Younis I, Van Der Hiel B, Schalij MJ, Van Der Wall E, Bax JJ, Mirza T, Raza M, Hashemizadeh H, Pollice PP, Djokovic A, Bonifazi MB, Pollice FP, Ferreira MJ, Santos L, Ramos D, Cunha MJ, Albuquerque A, Moreira A, Costa G, Providencia LA, Simic DV, Singh N, Krishna BA, Leccisotti L, Perna F, Lago M, Leo M, Pelargonio G, Bencardino G, Narducci ML, Casella M, Krotin M, Bellocci F, Giordano A, Kirac S, Yaylali O, Serteser M, Yaylali T, Okizaki A, Urano Y, Nakayama M, Ishitoya S, Savic-Radojevic A, Sato J, Ishikawa Y, Sakaguchi M, Nakagami N, Watanabe K, Aburano T, Solav SV, Bhandari R, Burrell S, Dorbala S, Pljesa-Ercegovac M, Leccisotti L, Bruno I, Caldarella C, Collarino A, Mattoli MV, Stefanelli A, Cannarile A, Maggi F, Giordano A, Soukhov V, Zdravkovic M, Bondarev S, Yalfimov A, Low CS, Notghi A, O'brien J, Khan M, Priyadharshan PP, Chandok G, Aziz T, Avison M, Saponjski J, Smith RA, Bulugahapitya DS, Vakhtangadze T, Todua F, Baramia M, Antelava G, Roche NC, Paule P, Kerebel S, Gil JM, Jelic S, Fourcade L, Tzonevska A, Tzvetkov K, Atanasova M, Parvanova V, Chakarova A, Piperkova E, Aktas A, Bahceci T, Yaman G, Simic T, Cinar A, Kocabas B, Kavak K, Gencoglu A, Muderrisoglu H, De Haan S, Knaapen P, Harms HJ, Lubberink M, Beek AM, Eckardt R, Lammertsma AA, Van Rossum AC, Allaart CP, Entok E, Simsek S, Akcay B, Ak I, Vardareli E, Stachura M, Kwasiborski PJ, Kjeldsen BJ, Horszczaruk GJ, Komar E, Cwetsch A, Nasr GM, Sliem H, Hayes Brown K, Alexander S, Green J, Zraik B, Jain S, Andersen LI, Aldaas F, Collado F, Alhaji M, Morales Demori R, Doukky R, Falcao A, Chalela WA, Azouri LO, Almeida ADJ, Ramires JAF, Haghfelt T, Meneghetti JC, Siqueira ME, Vieira E, Kelendjian J, Oliveira M, Alves F, Smanio P, Balogh I, Kerecsen G, Marosi E, Grupe P, Szelid ZS, Al-Mallah M, Sattar A, Swadia T, Chattahi J, Qureshi W, Khalid F, Peix A, Cabrera LO, Gonzalez A, Johansen A, Padron K, Carrillo R, Mena E, Fernandez Y, Hechavarria S, Rodriguez L, Takamura K, Fujimoto S, Nakanishi R, Yamashina S, Hesse B, Namiki A, Yamazaki J, Koshino K, Fukuda H, Hashikawa Y, Teramoto N, Hikake M, Ishikane S, Ikeda T, Iida H, Pena H, Dey T, Wieczorek H, Bippus R, Backus BE, Romijn RL, Verzijlbergen JF, Aach T, Takahashi Y, Oriuchi N, Higashino H, Cantinho G, Endo K, Mochizuki T, Murase K, Baali A, Moreno R, Chau M, Rousseau H, Nicoud F, Dolliner P, Brammen L, Wilk M, Steurer G, Traub-Weidinger T, Ubl P, Schaffarich P, Dobrozemsky G, Staudenherz A, Ozgen Kiratli M, Temelli B, Kanat NB, Aksoy T, Srour Y, Slavich GA, Piccoli G, Puppato M, Grillone S, Gasparini D, Danad I, Raijmakers PG, Appelman YE, Harms HJ, Van Kuijk C, Godinho F, Hoekstra OS, Lammertsma AA, Lubberink M, Van Rossum AC, Knaapen P, Dunet V, Perruchoud S, Poitry-Yamate C, Lepore M, Gruetter R, Zafrir N, Pedrazzini T, Prior JO, Anselm D, Anselm A, Atkins H, Renaud J, Dekemp R, Burwash I, Guo A, Williams K, Gutstein A, Beanlands R, Glover C, Vilardi I, Zangheri B, Calabrese L, Romano P, Bruno A, Barreiro Perez M, Martin Fernandez M, Fernandez Cimadevilla OC, Mats I, Leon Duran D, Florez Munoz JP, Velasco Alonso E, Luyando LH, Uusitalo VA, Kajander S, Saraste A, Luotolahti M, Wendelin-Saarenhovi M, Sundell J, Battler A, Raitakari O, Knuuti J, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Huidu S, Gadiraju R, Ghesani M, Uddin Q, Solodky A, Wosnitzer B, Takahashi N, Alhaj E, Legasto A, Abiri B, Elsaban K, El Khouly T, El Kammash T, Al Ghamdi A, Hommel H, Sari E, Feuchtner G, Pachinger O, Friedrich G, Mlynarska A, Mlynarski R, Wilczek J, Sosnowski M, Purvis JA, Hughes SM, Kyung Deok B, Singh N, Bon Seung K, Sang Geun Y, Chang Min D, Gwan Hong M, Vara A, Peters AM, De Belder A, Nair S, Ryan N, James R, Dizdarevic S, Depuey G, Friedman M, Wray R, Old R, Babla H, Chuanyong B, Maddahi J, Tragardh Johansson E, Sjostrand K, Edenbrandt L, Aguade-Bruix S, Cuberas-Borros G, Pizzi MN, Sabate-Fernandez M, De Leon G, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Casset-Senon D, Edjlali-Goujon M, Alison D, Delhommais A, Cosnay P, Low CS, Notghi A, O'brien J, Tweddel AC, Bingham N, O Neil P, Harbinson M, Lindner O, Burchert W, Schaefers M, Marcassa C, Campini R, Calza P, Zoccarato O, Kisko A, Kmec J, Babcak M, Vereb M, Vytykacova M, Cencarik J, Gazdic P, Stasko J, Abreu A, Pereira E, Oliveira L, Colarinha P, Veloso V, Enriksson I, Proenca G, Delgado P, Rosario L, Sequeira J, Kosa I, Vassanyi I, Egyed CS, Kozmann GY, Morita S, Nanasato M, Nanbu I, Yoshida Y, Hirayama H, Allam A, Sharef A, Shawky I, Farid M, Mouden M, Ottervanger JP, Timmer JR, De Boer MJ, Reiffers S, Jager PL, Knollema S, Nasr GM, Mohy Eldin M, Ragheb M, Casans-Tormo I, Diaz-Exposito R, Hurtado-Mauricio FJ, Ruano R, Diego M, Gomez-Caminero F, Albarran C, Martin De Arriba A, Rosero A, Lopez R, Martin Luengo C, Garcia-Talavera JR, Laitinen IEK, Rudelius M, Weidl E, Henriksen G, Wester HJ, Schwaiger M, Pan XB, Schindler T, Quercioli A, Zaidi H, Ratib O, Declerck JM, Alexanderson Rosas E, Jacome R, Jimenez-Santos M, Romero E, Pena-Cabral MA, Meave A, Gonzalez J, Rouzet F, Bachelet L, Alsac JM, Suzuki M, Louedec L, Petiet A, Chaubet F, Letourneur D, Michel JB, Le Guludec D, Aktas A, Cinar A, Yaman G, Bahceci T, Kavak K, Gencoglu A, Jimenez-Heffernan A, Sanchez De Mora E, Lopez-Martin J, Lopez-Aguilar R, Ramos C, Salgado C, Ortega A, Sanchez-Gonzalez C, Roa J, Tobaruela A, Nesterov SV, Turta O, Maki M, Han C, Knuuti J, Daou D, Tawileh M, Chamouine SO, Coaguila C, Aguade-Bruix S, Mariscal-Labrador E, Cuberas-Borros G, Sabate-Fernandez M, Pizzi MN, Kisiel-Gonzalez N, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Daou D, Tawileh M, Coaguila C, De Araujo Goncalves P, Sousa PJ, Marques H, O'neill J, Pisco J, Cale R, Brito J, Gaspar A, Machado FP, Roquette J, Alexanderson Rosas E, Jimenez-Santos M, Martinez M, Melendez G, Kimura E, Romero E, Pena-Cabral MA, Jacome R, Ochoa JM, Meave A, Alessio AM, Patel A, Lautamaki R, Bengel FM, Bassingthwaighte JB, Caldwell JH, Rahbar K, Seifarth H, Schafers M, Stegger L, Spieker T, Hoffmeier A, Maintz D, Scheld H, Schober O, Weckesser M, Aoki H, Matsunari I, Kajinami K, Martin Fernandez M, Barreiro Perez M, Fernandez Cimadevilla OV, Leon Duran D, Velasco Alonso E, Florez Munoz JP, Luyando LH, Ghadri JR, Pazhenkottil AP, Nkoulou RN, Husmann L, Buechel RR, Herzog BA, Wolfrum M, Gaemperli O, Templin C, Kaufmann PA, De Graaf FR, Schuijf JD, Veltman CE, Van Velzen JE, Kroft LJ, De Roos A, Reiber JHC, Jukema JW, Van Der Wall EE, Bax JJ, Venuraju S, Yerramasu A, Atwal S, Lahiri A, Kunimasa T, Shiba M, Ishii K, Aikawa J, Van Velzen JE, Schuijf JD, De Graaf FR, Kroner ESJ, Kroft LJ, De Roos A, Schalij MJ, Jukema JW, Van Der Wall EE, Bax JJ, Pontone G, Andreini D, Bertella E, Mushtaq S, Formenti A, Annoni AD, Ballerini G, Fiorentini C, Bartorelli AL, Pepi M, Ho KT, Yong QW, Chua KC, Panknin C, Roos CJ, Van Werkhoven JM, Schuijf JD, Van Velzen JE, Witkowska-Grzeslo AJ, Boogers MJ, Kroft LJ, De Roos A, Jukema JW, Bax JJ, Yerramasu A, Venuraju S, Anand DV, Atwal S, Dey D, Berman D, Lahiri A, De Graaf FR, Schuijf JD, Veltman CE, Van Werkhoven JM, Van Velzen JE, Kroft LJ, De Roos A, Jukema JW, Van Der Wall EE, Bax JJ, Mut F, Giubbini R, Lusa L, Massardo T, Iskandrian A, Dondi M, Sato A, Kakefuda Y, Ojima E, Adachi T, Atsumi A, Ishizu T, Seo Y, Hiroe M, Aonuma K, Kruk M, Pracon R, Kepka C, Pregowski J, Kowalewska A, Pilka M, Opolski M, Michalowska I, Dzielinska Z, Demkow M, Stoll V, Sabharwal N, Chakera A, Ormerod O, Fernandes H, Bernardes M, Martins E, Oliveira P, Vieira T, Terroso G, Oliveira A, Faria T, Ventura F, Pereira J, Fukuzawa S, Inagaki M, Sugioka J, Ikeda A, Okino S, Maekawa J, Uchiyama T, Kamioka N, Ichikawa S, Afshar M, Alvi R, Aguilar N, Ippili R, Shaqra H, Bella J, Bhalodkar N, Dos Santos A, Daicz M, Cendoya LO, Marrero HG, Casuscelli J, Embon M, Vera Janavel G, Duronto E, Gurfinkel EP, Cortes CM, Takeishi Y, Nakajima K, Yamasaki Y, Nishimura T, Hayes Brown K, Collado F, Alhaji M, Green J, Alexander S, Vashistha R, Jain S, Aldaas F, Shanes J, Doukky R, Ashikaga K, Akashi YJ, Uemarsu M, Kamijima R, Yoneyama K, Omiya K, Miyake Y, Brodov Y, Venuraju S, Yerramasu A, Raval U, Lahiri A, Berezin A, Seden V, Koretskaya E, Berezin A, Panasenko TA, Matsuo S, Nakajima K, Kinuya S, Veltman CE, Boogers MJ, Chen J, Delgado V, Van Bommel RJ, Van Der Hiel B, Dibbets-Schneider P, Van Der Wall EE, Garcia EV, Bax JJ, Rutten-Vermeltfoort I, Gevers MMJ, Verhoeven B, Dijk Van AB, Raaijmakers E, Raijmakers PGHM, Engvall JE, Gjerde M, De Geer J, Olsson E, Quick P, Persson A, Mazzanti M, Marini M, Pimpini L, Perna GP, Marciano C, Gargiulo P, Galderisi M, D'amore C, Savarese G, Casaretti L, Paolillo S, Cuocolo A, Perrone Filardi P, Thompson RC, Al-Amoodi M, Thompson EC, Kennedy K, Bybee KA, Mcghie AI, O'keefe JH, Bateman TM, Van Der Palen RLF, Mavinkurve-Groothuis AM, Bulten B, Bellersen L, Van Laarhoven HWM, Kapusta L, De Geus-Oei LF, Pollice PP, Bonifazi MB, Pollice FP, Clements IP, Hodge DO, Scott CG, Daou D, Tawileh M, Coaguila C, De Ville De Goyet M, Brichard B, Pirotte T, Moniotte S, Tio RA, Elvan A, Dierckx RAIO, Slart RHJA, Furuhashi T, Moroi M, Hase H, Joki N, Masai H, Kunimasa T, Nakazato R, Fukuda H, Sugi K, Kryczka K, Kaczmarska E, Kepka C, Dzielinska Z, Petryka J, Mazurkiewicz L, Kruk M, Pregowski J, Demkow M, Ruzyllo W, Smanio P, Vieira Segundo E, Siqueira M, Kelendjian J, Ribeiro J, Alaca J, Oliveira M, Alves F, Peovska I, Maksimovic J, Vavlukis M, Kostova N, Pop Gorceva D, Majstorov V, Zdraveska M, Hussain S, Djearaman M, Hoey E, Morus L, Erinfolami O, Macnamara A, Kepka C, Kruk M, Pregowski J, Opolski MP, Pracon R, Michalowska I, Ruzyllo W, Witkowski A, Demkow M, Berti V, Ricci F, Gallicchio R, Acampa W, Cerisano G, Vigorito C, Sciagra' R, Pupi A, Cuocolo A, Nasr GM, Sliem H, Collado FM, Alhaji M, Schmidt S, Maheshwari A, Kiriakos R, Hayes Brown K, Vashistha R, Mwansa V, Shanes J, Doukky R, Ljubojevic S, Sedej S, Holzer M, Marsche G, Marijanski V, Kockskaemper J, Pieske B, Alexanderson Rosas E, Jacome R, Jimenez-Santos M, Romero E, Pena-Cabral MA, Ochoa JM, Ricalde A, Alexanderson G, Meave A, Mohani A, Khanna P, Liu Y, Sinusas A, Lee F, Pinas VA, Van Eck-Smit BLF, Verberne HJ, Lammertsma AA, De Bruin CM, Windhorst AD, Pena H, Guilhermina G, Wilk M, Srour Y, Godinho F, Jimenez-Angeles L, Ruiz De Jesus O, Yanez-Suarez O, Vallejo E, Reyes E, Chan M, Hossen ML, Underwood SR, Karu A, Bokhari S, Aguade-Bruix S, Cuberas-Borros G, Pineda V, Gracia-Sanchez LM, Pizzi MN, Garcia-Burillo A, Garcia-Dorado D, Castell-Conesa J, Candell-Riera J, Zavadovskiy K, Lishmanov YU, Saushkin W, Kovalev I, Chernishov A, Pontone G, Andreini D, Cortinovis S, Bertella E, Mushtaq S, Annoni A, Formenti A, Bartorelli AL, Fiorentini C, Pepi M, Tarkia M, Saraste A, Saanijoki T, Oikonen V, Savunen T, Green MA, Strandberg M, Teras M, Knuuti J, Roivainen A, Gaeta MC, Fernandez Y, Artigas C, Deportos J, Geraldo L, Flotats A, La Delfa V, Carrio I, Wong YY, Lubberink M, Ruiter G, Knaapen P, Raijmakers P, Laarse WJ, Vonk-Noordegraaf A, Izquierdo Gomez MM, Lacalzada Almeida J, Barragan Acea A, De La Rosa Hernandez A, Juarez Prera R, Blanco Palacios G, Bonilla Arjona JA, Jimenez Rivera JJ, Iribarren Sarrias JL, Laynez Cerdena I, Dedic A, Rossi A, Ten Kate GJR, Dharampal A, Moelker A, Galema TW, Mollet N, De Feyter PJ, Nieman K, Andreini D, Pontone G, Mushtaq S, Formenti A, Bertella E, Annoni A, Ballerini G, Fiorentini C, Pepi M, Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Trabattoni D, Bertella E, Annoni A, Formenti A, Fiorentini C, Pepi M, Broersen A, Frenay M, Boogers MM, Kitslaar PH, Van Velzen JE, Schuijf JD, Dijkstra J, Bax JJ, Reiber JHC, Pontone G, Andreini D, Mushtaq S, Bertella E, Annoni DA, Muratori M, Fusari M, Ballerini G, Bartorelli AL, Pepi M, Masai H, Moroi M, Johki N, Kunimasa T, Tokue M, Nakazato R, Furuhashi T, Fukuda H, Hase H, Sugi K, Dharampal AS, Weustink AC, Rossi A, Neefjes LAE, Papadopoulou SL, Chen C, Mollet NRA, Boersma EH, Krestin GP, De Feyter PJ, Purvis JA, Sharma D, Hughes SM, Zafrir N, Maddahi J, Berman DS, Taillefer R, Udelson J, Devine M, Lazewatsky J, Bhat G, Washburn D, Yerramasu A, Patel D, Mazurek T, Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F, Fukuda H, Moroi M, Masai H, Kunimasa T, Nakazato R, Furuhashi T, Sugi K, Harbinson MT, Wells G, Dougan J, Borges-Neto S, Phillips H, Farzaneh-Far A, Starr Z, Shaw LK, Fiuzat M, O'connor C, Henzlova M, Duvall WL, Levine A, Baber U, Croft L, Sahni S, Sethi S, Hermann L, Allam AH, Wann LS, Thompson RC, Nureldin A, Gomaa A, Badr I, Soliman MAT, Hany HAR, Sutherland ML, Thomas GS, Yiu KH, Schuijf J, Van Werkhoven JM, De Graaf F, Pazhenkottil A, Jukema JW, Bax JJ, De Roos A, Kroft LJ, Kaufmann PA, Kroner ESJ, Van Velzen JE, Boogers MJ, Siebelink HMJ, Schalij MJ, Kroft LJ, De Roos A, Reiber JH, Schuijf JD, Bax JJ, Ayub M, Naveed T, Azhar M, Van Tosh A, Faber TL, Votaw JR, Reichek N, Pulipati B, Palestro C, Nichols KJ, Einstein AJ, Khawaja T. Abstracts. Eur Heart J Suppl 2011. [DOI: 10.1093/eurheartj/sur013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|